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Translational biomedical informatics is the application of computational methods 
to facilitate the translation of basic biomedical science to clinical relevance. An example 
of this is the multi-step process in which large-scale microarray-based discovery 
experiments are refined into reliable clinical diagnostic tests. 
The quality of microarray data is a major issue that must be addressed before 
microarrays can reach their full potential as a clinical molecular profiling tool for 
personalized and predictive medicine. The FDA has completed phase-I of the MicroArray 
Quality Control (MAQC) project, and is currently developing guidelines and standards on 
microarray data reporting, quality control, and data analysis [1]. The current status of 
microarray quality control (QC) and noise reduction however, is still a controversial 
collection of tools and methods. While competing model-based tools such as dChip [2, 
3], MAS5.0 [4], RMA [5, 6], and PLIER [7] have been developed to improve the quality 
of microarray gene expression data, these tools fall short in two important areas (1) they 
do not incorporate adequate spatial information into the outlier detection methods and (2) 
they do not incorporate outlier information into their normalization routines.  The 
methodology discussed in this dissertation, called caCORRECT, addresses these 
deficiencies and seeks to replace or augment existing technologies in order to improve 
the translation of microarray data to clinical relevance [8-12]. 
As a case study to validate and demonstrate the usefulness of caCORRECT, the 
entire workflow of biomarker discovery was executed for the clinical problem of 
classifying Renal Cell Carcinoma (RCC) specimens into appropriate subtypes [13, 14]. 
 xiii 
Two biomarkers are discovered, NNMT and PRKAB1, which are able to separate the 
chromophobe and clear cell subtypes of RCC with perfect accuracy for all of the samples 
tested. To translate this discovery into a clinically relevant test, improvements are made 
to the reliability of quantum dot based immunohistochemistry [15, 16]. 
 
 





 The central theme of this dissertation is the quality control of translational 
biomedical data, with a focus on gene microarrays and quantum dot 
immunohistochemistry, in an effort to improve reproducibility and reliability. To 
understand the potential impact of quality control, it is important to study it in the context 
of its use. This introduction aims to give the reader proper context, beginning with a 
definition of translational bioinformatics, followed by a description of the typical 
microarray experiment. We then discuss the current state of art in microarray quality 
control, followed by an overview of microarray biomarker selection, including the 
machine learning topics of classification and feature selection which are essential to 
developing high impact clinical solutions. Finally, we end with a discussion of an 
emerging frontier of translational biomedical informatics quality control—quantum dot 
based immunohistochemistry. Some of the work in this chapter is based upon my 2006 
book chapter on microarray analysis [17],  and my 2009 paper on quantum dot quality 
control [15]. 
Translational Bioinformatics 
 The ultimate goal of microarray analysis is the generation of reliable clinically 
relevant markers for disease and associated decision rules. This is a multi-step process 
that converts raw microarray data into biomarkers for clinical use. Proper and rigorous 
computational analysis is essential to the repeatability, reproducibility, and reliability of 
microarray data [18-35]. A schematic of the Translational Bioinformatics Pipeline is 
shown in Figure 1. First, raw microarray data are converted into useful gene expression 
data using any number of regression methods. Values of gene expression from multiple 
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biological samples are then used to select important features or to build predictive rules 
called classifiers. The results of feature selection and classification are lists of biomarkers 
that are appropriate for classifying the data into groups such as benign or malignant. 
These biomarker candidates are then validated through more specific measurement 
techniques such as PCR, and later Quantum Dot (QD) Immunohistochemistry (IHC). 
This dissertation aims to improve the reproducibility and reliability of the translational 
bioinformatics pipeline with novel contributions to the quality control of microarray data 
as well as QD-IHC. 
 As seen in the figure, microarray analysis is modular, and a small improvement in 
any step of the process has the potential to increase the performance of other steps 
downstream. Furthermore, the process is highly computational in nature due to the large 
volume of data (more than 200,000 probe measurements per chip) that must be analyzed. 
The translational nature of the pipeline is due to the increasing clinical relevance of 




Figure 1: Translational Bioinformatics Pipeline. 





 Microarray analysis is a fast growing field, simultaneously harnessing advances in 
semiconductor manufacturing, molecular biology, medicine, and computation to provide 
an unprecedented genome-wide view of a biological sample. For the past ten years, 
microarrays have promised that the information from a single microarray might be used 
to tell a doctor if a patient has cancer, what type of cancer it is, what the prognosis is, and 
what drug to use to best fight the cancer. As the field has matured, however, serious 
questions have been raised as to the reproducibility and reliability of microarray based 
prediction. Although the FDA has endorsed the use of microarrays as a clinical profiling 
tool [1], others have disagreed [30], and a major drawback of microarray technology 
remains that it is less accurate and less reproducible than other RNA quantification 
procedures such as PCR [1, 25, 28, 36]. The main goal of this dissertation work is to help 
microarrays achieve their full potential as reliable clinical profiling tools by leveraging 
novel quality control methods to improve the reproducibility of results. 
 A DNA microarray is, generally speaking, a matrix of short oligonucleotide 
probes attached to a hard surface for the purpose of selectively hybridizing with unknown 
DNA in a solution. Some of the first microarrays used for genotyping, such as those 
constructed in 1995 by Schena et al. were printed on glass slides with custom-built high-
speed arraying machines [37]. The design, selection, length, construction and attachment 
of these probes vary depending on experimental design, and can be very diverse 
depending on the application. Affymetrix, for example uses photolithography to attach 
sets of different twenty-five base pair probes in different locations on a single chip. See 
Figure 2 and Figure 3 for cartoons of Affymetrix microarray layouts. Other 
manufacturers, such as Affymetrix’s leading competitor, Illumina, prefer to use longer 
cDNA probes attached to an array of beads on a bed of fiber optics. Evolving from 
Southern blotting, DNA microarrays are able to achieve much higher densities of 
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information-gained per sample-used than other techniques such as blotting or PCR. 
Microarrays achieve this density through the creative application of semiconductor 
manufacturing techniques, pioneered by companies such as Affymetrix in the early 
1990’s. Modern microarrays are manufactured by many different companies, and can be 
constructed on glass, plastic or silicon microchips. 
In addition to the DNA microarray, protein microarrays have also been 
constructed in recent years using similar technology. Protein arrays consist of specific 
agents spotted to a surface that attempt to selectively hybridize with proteins in an 
unknown solution. Protein microarrays can be spotted with monoclonal antibodies to 
determine the concentration of protein in a sample, or functional proteins can be spotted 
to the array to determine protein-protein interactions. While protein microarrays differ 
from DNA microarrays in what they target, they serve similar and parallel roles in the 
type information they provide. For the purposes of this document, we will discuss 
microarray analysis in the context of DNA microarray analysis, especially those 
manufactured by the most popular vendor, Affymetrix, but the same concepts and 
strategies will apply reasonably well to any quantitative microarray platform with only 




Figure 2: Cartoon Depicting a Single Feature on an Affymetrix GeneChip® Microarray. 
Image courtesy of Affymetrix.  
 




Figure 3: Cartoon Illustrating Microarray Probe Layout.  
Square-toothed lines represent single stranded DNA. The top panel shows how multiple 
probes target a single gene sequence. The bottom panel shows how the probes of a single 
probe set are arranged on modern and older Affymetrix arrays. Note that the typical gene 
is measured by 20+ probes, and the typical array has more that 500x500 different probes 
printed on it. Perfect match (PM) and mismatch (MM) probes are shown in dark and light 





 The basic procedure for using a DNA microarray is as follows. First, RNA is 
extracted from a biological sample. Next, the RNA is amplified to create fluorescently-
labeled, complimentary cDNA, which is much more stable than RNA. The cDNA 
solution is then washed over the microarray and allowed to hybridize with the probes on 
the array (see Figure 4). The complimentary-base pairing of DNA is such that only 
cDNA that is a specific match for the probes on the array can attach properly. Even a 
single mismatch in a sequence will lead to suboptimal hybridization. In fact, Affymetrix 
arrays are designed with built in “mismatch” (MM) control sequences adjacent to each 
“perfect match” (PM) sequence to act as controls for non-specific binding. Unattached 
cDNA is then rinsed from the microarray, leaving only fluorescent cDNA that is 
complimentary to the probes on the microarray. A laser is then used to read the 
fluorescence levels at every spot on the array. These fluorescence levels are then 
quantified and collated with the probes they represent, and this “probe intensity” data is 




Figure 4: Cartoon Illustrating Microarray Probe Hybridization.  
Square-toothed lines represent single stranded DNA. Perfect match (PM) and mismatch 
(MM) probes are shown in dark colors, while fluorescent cDNA from the sample being 
tested is shown in lighter shades. The two strands shown for each location are only 
indicative of the millions of probes on an actual microarray. MM pairs are indicated by a 




 Microarrays can be adapted to form a comparative study by using two samples 
simultaneously tagged with two differently colored fluorescent markers. These samples 
can then be assayed on the same chip and viewed with a dual-color scanner. Relative 
fluorescence values between colors are then recorded instead of absolute fluorescence for 
a single-color experiment. This work chooses to focus on single-color microarray data, 
but it would be fairly straightforward to adapt to dual-channel arrays as well. 
 The main advantage of the microarray is that it offers high-throughput genome-
wide analysis by simultaneously measuring the expression levels of tens-of-thousands of 
different transcripts. Microarrays are capable of generating such vast amounts of data that 
they have the potential to eclipse the previous paradigm of single-target experimentation. 
Before microarrays, the prospect of a scientist beginning even a few hundred ‘shot in the 
dark’ gene expression experiments would have been ludicrous, but now with microarrays 
this can be performed relatively easily, yielding results in a matter of days. 
 One shortcoming of microarrays is that they offer primarily a tissue-wide view, 
meaning that single-cells cannot be viewed without significant RNA amplification that 
can alter relative expression levels of transcripts within the cell. Further complicating 
matters, standardization of RNA extraction and amplification is not perfect, and 
microarrays prepared in different laboratories often carry bias that clouds results [36]. In 
addition to variation in procedure, there is also wide variation in the microarrays 
themselves. Multiple platforms exist to choose from, with multiple companies offering 
different designs and libraries of transcripts. Some companies offer customized 
microarrays with user-specified transcripts, yet many researchers choose to print their 
own arrays. This variation in chip makeup makes it very difficult to compare results with 
other laboratories. To help combat standardization issues, a standard for Minimum 
Information About a Microarray Experiment (MIAME) was proposed in 1999, and is still 
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being improved today. More information on MAIME, and the current MAIME standard 
checklist can be found at http://www.mged.org/Workgroups/MIAME/miame.html [38]. 
Manufacturing inconsistencies such as those that arise from the tips used to print the 
microarrays, or inconsistencies in the washing and drying procedures, also contribute to 
noise that can seriously hamper results. To correct for chip noise, a variety of statistical 
and quality control methods have been proposed, and are discussed later [5, 6, 12, 25, 39-
50]. 
 The microarray is a diverse platform, and can be used in a variety of experiments. 
Some of the earliest experiments to use microarrays studied gene expression during the 
life cycle of yeast [51]. Modern experimentation, however, has expanded to comparative 
studies such as healthy versus cancerous tissues, or time-series analysis studying the 
progression of disease. While applications may vary, the most common task for a 
microarray experiment is to identify a small set of “biomarker” genes that can 
differentiate between two or more varieties of biological sample. These interesting genes 
can then be used as targets for more specific assays to be used as screening tests, or the 
genes may be studied further to learn more about the mechanisms governing the problem 
at hand. 
 As with any experiment, repetition and balance are essential to successful results. 
This may be especially important with microarrays, because of their sensitivity to 
manufacturing defects or errors in preparation. Unfortunately, due to the relatively high 
cost of microarrays, many researchers cannot afford such extensive repetition and cross-
validation. Fortunately, depending on the problem being investigated, different 
experimental setups may be used to maximize the resources available. The problem of 
optimal design is especially relevant when multiple treatments and two-channel arrays 
are used. While the first instinct might be to use a procedure where all samples are 
compared to one reference, it has been shown that when larger (n>5) numbers of 
treatments are studied, loop and modified loop designs perform better than the standard 
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reference design. Furthermore, while it is clear that using more microarrays for an 
experiment is better, there are exceptional gains in marginal efficiency when two more 
(n+2) or twice as many (2*n) arrays are used [52]. In the end, however, even the best of 
experimental designs can be crippled by laboratory or manufacturing error, resulting in 
noisy or defective data and poor results. This effect can be alleviated with proper quality 
control and assessment procedures like the ones proposed in this document. 
Microarray Quality Control 
 The quality of microarray data is a major issue that must be addressed before 
microarrays can reach their full potential as a clinical molecular profiling tool for 
personalized and predictive medicine. The FDA has completed phase-I of the MicroArray 
Quality Control (MAQC) project, and is currently developing guidelines and standards on 
microarray data reporting, quality control, and data analysis [1]. The current status of 
microarray quality control (QC) and noise reduction however, is still a controversial 
collection of tools and methods. 
 Much work has already been done to try to improve the accuracy of derived gene 
expression data from microarray chips. Efforts can be generally categorized into two 
strategies: (1) array Quality Assessment (QA) methods, and (2) robust gene expression 
calculations. The comprehensive system proposed in this dissertation, caCORRECT, 
uniquely falls into both categories. Table 1 shows a comparison of features for 
caCORRECT and popular QA methods, whereas Table 2 shows a comparison of features 
for caCORRECT and popular gene expression calculation methods. 
 In one of the earliest attempts at array quality assurance, Yang et al. proposed a 
model based method for flagging statistical “weak spots” on dual-color spotted arrays 
[44]. Yang’s method’s main goal was to eliminate nonsensical ratio measurements made 
from probes with very low intensity values. Yang et al.’s method is worth mentioning in 
particular, because it is the closest published example to caCORRECT’s artifact aware 
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normalization scheme. Yang et al. describe a way to estimate a scaling factor for use on 
the different-colored intensities of two-color arrays by ignoring “weak” probes. Here, 
they make the assumption that all of their “weak” probes are manufacturing errors and 
thus should not factor into the scale factor calculation. While similar in concept to 
caCORRECT’s scheme, it is rather trivial in comparison, and relies on human selection 
of threshold values for “weak” spot detection. Furthermore, the normalization for Yang’s 
method is completely isolated from outlier detection, whereas caCORRECT’s 
normalization is allowed to iteratively improve the sensitivity of outlier detection.  
 A serious flaw in all of the most popular gene expression calculations is that they 
do not incorporate spatial chip layout information into their outlier identification 
schemes. One QA method that does take spatial effects into account is that of Reimers 
and Weinstein, which was later named SmudgeMiner [40]. This system can be used to 
visualize regional biases across high-density chips. Citing factors such as temperature, 
liquid flow rate, RNA diffusion rate, and edge effect, they showed that significant 
regional biases are common. In addition to localized background calculation, 
SmudgeMiner produces a comprehensive quality score for each chip by measuring the 
correlation of each probe’s expression level to that of its neighbors. While this 
application may provide quality score information, it does not allow correction of these 
artifacts. Users are then faced with a difficult choice: abandon a chip, or proceed knowing 
that artifacts exist. Another system, arrayMagic [48] has the same drawbacks as 
SmudgeMiner i.e. merely assessing quality without providing an avenue of improvement 
beyond discarding whole chips.  
 In the development of new methods for  microarray QA, Brodsky et al. proposed 
a novel method of using clustering of gene expression profiles across microarrays to 
indicate quality [53]. First, gene expression profiles are clustered, and then the 
randomness of the clusters’ distributions across the microarrays are measured. Second, 
the spatial distributions of high and low expressed genes are monitored on each sample 
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for randomness. These two qualities are then used to identify artifactual genes. While 
Brodsky’s method does include intelligent use of chip layouts for artifact detection, it 
falls short as a major contributor to modern translational bioinformatics by not supporting 
Affymetrix arrays. Furthermore, its methodology for dealing with artifactual data (a local 
mean replacement) is trivial, and of debatable use in comparison to caCORRECT’s more 
informed model-based imputation. Furthermore, neither the method of Brodsky et al. nor 
any of the other quality assessment methods surveyed here have been applied to the 
Illumina platform, although caCORRECT has [10].  
 The best attempt to date (other than caCORRECT) at spatial outlier detection for 
Affymetrix arrays is a system called Harshlighting [41, 50], which was published after 
my first attempt at spatial outlier detection [8, 9], after the launch of what is now the 
caCORRECT website (at the time, called ChipQC, and later PADRE), but before journal 
publication of the definitive caCORRECT paper [11]. Harshlighting is similar to 
caCORRECT in that it leverages image processing techniques such as sliding windows 
and background assessment to identify an assortment of compact and diffuse artifacts. 
Harshlighting, however, performs image processing on an error image which is a simple 
distance from the median. Not only does this formulation ignore the natural variance of 
probes, but it also neglects to account for global chip to chip variation which may lead to 
whole chips being discarded that may be correctable with a simple normalization step. 
Furthermore, the authors of Harshlighting point out the appearance of “ghosting” artifacts 
i.e. the incorrect appearance of artifacts on clean chips as a result of comparison to a 
severe artifact on a different chip in a batch. Whereas Harshlighting attempts to correct 
for this phenomenon by using a median in its error heat map calculation (as opposed to 
the more outlier-sensitive measure, the arithmetic mean), caCORRECT completely 
avoids the problem by iteratively identifying artifacts and omitting them from 
calculations altogether (see equations 2.1-2.4 for details). 
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 In summary, highlighted by Table 1, caCORRECT represents an improvement 
over existing QA methods by (1) global normalization before outlier identification, (2) 
model-based outlier replacement, (3) iteration of outlier removal and normalization, and 
(4) application to the two leading chip manufacturers, Affymetrix and Illumina. 
The second front of microarray quality control is robust gene expression 
calculation. Affymetrix microarrays, for example can be processed with Affymetrix’s 
own Microarray Suite (MAS5.0) [4], GeneChip Operating Software (GCOS), or Probe 
Logarithmic Error Intensity Estimate (PLIER) [7], but alternatives such as dChip [39], 
PerfectMatch [54], and RMA [5, 6] also exist. These programs include good quality 
control measures such as normalization, background correction, and robust model fitting 
in an attempt to determine gene expression from multiple probe values. Many of them 
provide a visualization feature showing where outlier probes are located on the chips, but 
yet they (1) do not include this spatial information in their outlier detection, and (2) they 
do not incorporate outlier information into their probe normalizations (see Table 2). This 
is troubling, considering the existing body of knowledge on spatial chip artifacts, 
including one study which showed that gene co-expression results were found to be 
correlated with the proximity of genes on the microarray chip, an otherwise randomized 
event [56]. A gallery of such spatial artifacts (derived from caCORRECT artifact heat 
maps) can be found at the ArrayWiki website: arraywiki.bme.gatech.edu [57] or at the 
RMA express image hall of fame page at plmimagegallery.bmbolstad.com [58]. 
dChip includes methods for statistical detection of array, probe, and spot artifacts, 
but does not include spatial information in its algorithms, nor does it incorporate outlier 
information into its normalization scheme. RMA as well lacks these innovations which 
are provided by caCORRECT. Furthermore, the global normalization scheme employed 
by dChip, which selects a single chip as a template for normalization, is especially prone 
to the pitfalls of normalization in the presence of artifacts, just as RMA’s quantile 
normalization, which is later discussed in chapter 2, Figure 10. 
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While the popular tools dChip and RMA suffer from warping in the presence of 
artifacts due to their chosen normalization techniques, MAS5.0 skirts the problem by not 
normalizing probes at all. Accordingly, MAS5.0 has been shown to be less accurate than 
dChip or RMA [5, 49, 50, 59], but it remains popular for clinical applications where its 
ability to process one chip at a time is appealing. 
Table 2 shows areas of novel protocol improvements with respect to existing gene 
expression calculation software. We will later support the claim that these innovations are 
indeed improvements in chapter 3 as we give evidence that shows caCORRECT 
improves the accuracy of gene expression and the reliability of biomarker discovery over 
RMA and MAS5.0. We chose to focus on these two methods due to their overwhelming 
popularity among FDA MAQC phase II participants (data not shown). 
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Microarray Analysis and Biomarkers 
 Microarray analysis is, essentially, a pattern recognition problem with two goals. 
The first goal is classification—‘given a sample of unknown type, what class does the 
sample belong to?’  The second goal is the more fundamental goal of feature selection—
‘which features carry the most information to help us in the problem of classification?’  
These two goals of classification and feature selection are not independent, and just as the 
success of classification relies on good features, feature selection may receive feedback 
from the success of classifiers.  
 In the language of microarray analysis, features refer to genes-- expression levels 
of RNA as measured by a microarray. A single observation of the feature vector is the 
sample, which is RNA from a biological source, such as a tissue biopsy measured via a 
single microarray. Multiple samples comprise the many data points of the dataset, which 
is often divided into training and testing subsets for further analysis. In the context of 
microarrays, classes can include normal or diseased tissue, malignant or benign cancers, 
or even subclasses of cancers which may aid physicians in selecting appropriate 
treatment.  
Classification 
 Sample classification can be done in an unsupervised or supervised manner. 
Unsupervised methods make no assumptions about the correct class of a sample, but 
attempt to group samples into classes based on their similarity or distances from one-
another. Supervised methods, on the other hand, attempt to learn a decision rule from a 
training set of labeled data, and then use that rule to classify unknown samples in the test 
set. While supervised methods generally produce more powerful classifiers, unsupervised 
methods can be useful in discovering previously unidentified subtypes. These techniques 
are not mutually exclusive, and clustering (an unsupervised method), for example can be 
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helpful as a first step before further analysis or as an intermediate step in more powerful 
supervised techniques such as SAM or SVM.  
 While a survey appears below, more general discussions of modern pattern 
classification methods are widely available in texts such as Pattern Classification by 
Duda Hart and Stork [61]. 
Hierarchical Clustering 
 One of the simplest and most common forms of unsupervised classification is 
hierarchical clustering. Hierarchical clustering is performed by iteratively grouping the 
two closest samples as determined by a distance metric. Euclidian distance and 
correlation are two commonly used distance metrics, but many others exist. The iterative 
grouping of samples continues until one of two conditions is met: 1) the number of 
clusters equals the desired number of class separations, or 2) the distance between 
clusters reaches some threshold. The results of hierarchical clustering can then be 
incorporated into a simple prediction rule: an unknown sample is assigned to the class 
which it is nearest to. While hierarchical clustering is fast and simple, it becomes 
decreasingly useful with smaller sample sizes, or poorly separated classes.  
K-means Clustering 
Another unsupervised classification commonly used is k-means clustering. K-
means clustering attempts to minimize the distortion of each class by iteratively 
recomputing class centers using an Expectation-Maximization approach. K-means 
clustering has the advantage of allowing the user to specify the number of clusters that 
they are looking for, and the advantage of finding optimal or near-optimal clusters. This 
generally leads to better results for classification than a hierarchical cluster. Specifying 
the number of classes could be a disadvantage, however if the goal of clustering is to 
identify new subclasses of disease. 
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SAM/PAM 
 Significance Analysis of Microarrays (SAM) and Prediction Analysis of 
Microarrays (PAM) are two recently proposed methods of feature selection designed 
specifically for microarrays. SAM, developed by Tusher, Tibshirani and Chu, generates a 
SAM test statistic for each gene [62]. The SAM statistic is like a t-statistic, but uses a 
small positive constant added to the standard deviation in the denominator. This addition 
artificially increases the variance so that the test is less likely to pick up genes with very 
low, hard to duplicate expression levels as significant. The significance of this SAM test 
statistic is calculated with a permutation test, which tells how rare the calculated test 
statistic is among simulated statistics calculated from randomly relabeled samples. SAM 
then provides a ranking of the genes by ordering the significance of the SAM statistic. 
While SAM and other statistical methods, such as fold change or t-test p-value 
thresholding, are good at finding differentially expressed genes, they can discard 
potentially important genes with more nonlinear, yet significant characteristics. 
 The other method created by the Tibshirani group, PAM, uses soft thresholding to 
“shrink” the list of genes until only a core of useful genes remains [63]. This shrinking 
process is accomplished by eliminating genes from the classifier if the gene’s expression 
centroid is similar for all classes. The resultant shrunken list of genes then have more 
distinct centroids than the original gene list, and are thus better-suited features for 
classification. To classify an unknown test sample using PAM, only the shrunken list of 
genes are used as features.  The test sample is then placed into the class where the 
distance between the test sample and class centroid is minimized. A correction factor may 
also be added to account for the a priori probability of class membership.  PAM, like 
SAM, also results in a ranking of significant genes, which may be good features choices 
for a classifier. 
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Support Vector Machines 
 A support vector machine (SVM) is a classifier in which a maximal margin 
hyperplane is generated that separates multiple classes of data points[64].  The traditional 
form of the SVM problem handles only two classes, but may be extended to more than 
two classes. Data points can be multidimensional without greatly affecting processing 
performance of the algorithm, which makes the SVM well suited for microarray data 
points, which may consist of thousands of features. Furthermore, SVM generalizes well 
even for small sample sizes, which is usually the case with microarray experiments. A 
major advantage of SVM over other methods is that through the use of a kernel function, 
the SVM is able to make use of linear and nonlinear trends in the data. The nonlinear 
capabilities of SVM are especially showcased when analyzing multiple features. In this 
case, subtle biochemical interactions such as inhibition, activation, and redundant 
function can be seen and used to create complex, nonlinear classification rules. In 
addition to being used for classification, the SVM can also be used effectively for 
wrapper-based feature selection as discussed later in the “Feature Selection” section. The 
versatility and scalability of the SVM combine to make it an attractive and popular choice 
for microarray analysis. 
Feature Selection 
 Feature selection in the context of microarray analysis is synonymous with 
finding a set of differentially expressed genes. Because these genes will ultimately be 
used as input to a classifier, feature selection can also be thought of in the context of 
supervised analysis. If each gene is used independently to build a classifier, it follows that 
the genes which produce classifiers with lowest error in prediction rates contain the most 
discriminating information, and are thus good candidates to serve as biomarkers. This is 
the basis of filter methods of feature selection. Alternatively, the best performing set of 
features is not necessarily composed of the set of the best individually-performing 
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features. Finding such a best performing set of genes is the basis of wrapper methods of 
feature selection.  
 For filter methods, features are selected or ranked individually based on their 
independent discriminatory power. Common methods for ranking include the p-value 
from a t-test, the observed fold change of gene expression between classes, or the 
estimated error of a single-feature classifier using just that gene. After ranking genes, a 
binary selection criteria, such as “top 50 genes” or “all genes with fold change greater 
than 2” is applied to create a list of features on which to build a predictive model. Filter 
methods are considered suboptimal in that they do not account for interactions among 
features. This is an especially big problem in the context of gene microarray data, which 
are known to be highly co-regulated, highly networked, and thus not independent. Using 
filter methods may, therefore, lead to selection of redundant features which add 
complexity without adding discriminating power. For this reason, wrapper methods are 
sometimes preferred. 
 For wrapper methods, features are evaluated in sets for their combined ability to 
contribute to a successful classifier. To begin, a classification method and an error 
estimation technique are selected, and then used to rank perspective feature sets based on 
the error estimate of classification.  The typical microarray has on the order of thousands 
of genes, which makes an exhaustive search of even pair wise feature sets a daunting 
task. Exhaustive searches of sets larger than 3 or 4 are usually impossible to complete in 
a reasonable time. To counter the factorial growth of exhaustive searches, other 
optimization routines, such as iterative feature addition/subtraction or genetic algorithms 
may be employed [65]. 
Error estimation 
 When assessing the performance of any classifier, it is important to know how 
reliable the classifier is, or, more precisely, how accurately will the classifier perform 
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given new, unknown input? At the root of this question lies the selection of an error 
estimation method—the method used to estimate what the error rate of the classifier 
would truly be in a real application. While an improperly low error estimate during 
feature selection will lead to false-positive results, and can lead to fruitless and costly 
validation studies, an improperly high error estimate will lead to false-negative results, 
and may exclude a useful feature from selection. In the context of microarray analysis, 
false-positive results are undesirable and costly but may be corrected via proper 
validation. False-negative results, on the other hand, cannot be recovered from because 
they will not be investigated any further. Another important property of error estimation 
is that it is often integral in the design of the classifier itself, because it can be a necessary 
parameter for feature selection, selecting modeling parameters, or even convergence of 
the classifier. Fortunately, many different strategies of error estimation exist, such as 
resubstitution, cross-validation, and bootstrapping [35, 66]. 
 The selection of an appropriate error estimator involves a delicate balance of 
computational effort, bias, and variance. Some methods, such as resubstitution provide 
under-estimates of the true error, while others such as bootstrapping are often biased 
towards high estimates of the true error of classification. Besides bias, variance is also an 
important characteristic to consider when choosing an appropriate error estimator. Even if 
the error estimate is unbiased, a high variance will undermine results by often estimating 
an error that is far from the true error. Finally, computational cost must also be 
considered when selecting an error rate estimator. Often the best, most accurate error 
estimation methods involve repetitive sampling of training and testing datasets for each 
feature set being analyzed. With each iteration, a new classifier must be built, which will 
slow down the overall progress of the algorithm. Methods such as resubstitution, however 
offer minimum computational effort because they require only one classifier to be built 
for each feature set. For problems with large search spaces, such as finding an optimal 
combination of biomarkers, the computational costs of error estimation have an even 
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larger impact, and the added accuracy of good estimation may be eclipsed by the 
practicality of simpler methods. 
Resubstitution 
 Perhaps the simplest method of error estimation and one of the most 
computationally inexpensive methods is resubstitution. Resubstitution is by definition the 
use of the entire dataset as both the training and testing dataset. This is equivalent to a 
student receiving an exact copy of the final exam to study from before he actually takes 
the test. In the same way that the student would likely score higher on the exam than he 
would have on random questions, the results of a resubstitution estimated error will be 
generally optimistic. As a corollary, the more complex or prone to over-fitting that the 
classifier is the worse that the resubstitution will perform by allowing the over fitting to 
proceed unchecked. It is usually a bad idea to use resubstitution to estimate classifier 
error, especially when the ratio of features to samples is low. 
Cross Validation 
 As an alternative to resubstitution, cross validation attempts to correct for bias by 
separating testing and training sets. A k-fold cross-validation consists of dividing the data 
into k subsets, assigning one subset to be the testing set, and the remaining k-1 subsets as 
the training set. Cross validation can be run in either a complete or iterative manner. A 
complete cross validation executes exactly k times for a k-fold cross validation. In other 
words, once it divides up the data, it systematically leaves each subset out of the training 
set until each subset has taken its turn as the test set exactly once. A special case of 
complete cross validation is the ‘complete-leave-one-out’, or ‘n-fold cross validation’.  In 
this case, each single data point is left out exactly once, and the result is a nearly unbiased 
estimate of how the feature set might perform given brand-new data. With complete 
cross-validation, the number of classifiers that must be built for each error estimation is 
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capped at k. This is not the case for an iterative cross validation, in which many different 
partitions of the data into training and testing datasets are made. Iterative cross 
validations can, for example perform 100s or 1000s of independent segregations of the 
data, each time choosing a different set of data to act as the testing subset and the 
remainder to act as training data.  
Bootstrapping 
 Another error estimation method similar to cross-validation is bootstrapping. 
Bootstrapping involves selection, with replacement of n samples from a dataset of size n. 
The classifier is built on the chosen n samples (including some duplicates), and the error 
is estimated on those samples which were not selected for training. Like cross-validation, 
this bootstrap procedure may be performed iteratively in order to increase the reliability 
of the error estimate. Also like cross-validation, bootstrap estimates tend to be slightly 
pessimistic estimates of classifiers built using all of the data, because the bootstrap 
classifiers are trained on smaller subsets of the data, and classification accuracy generally 
improves with sample size. To offset the pessimistic nature of bootstrapping, 
bootstrapping can be combined with the optimistic result of resubstitution in the ratio 
63.2% bootstrap error to 36.8% resubstitution error to give the “632+ bootstrap” error 
estimation[67]. Because of this combination strategy, the 632+ bootstrap has the 
desirable property of being neither optimistic nor pessimistic and generally outperforms 
other methods in terms of both bias and variance [68]. Unless otherwise stated, all error 
estimates used in this dissertation are 632+ bootstrap estimations. 
Information Leakage 
 For any type of feature selection method, care must be taken to separate the 
feature selection step from the error estimation step [23, 34, 69]. In other words, any 
samples which are used for estimating the error of a classifier must not have been used 
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either in the training of the classifier or in the selection of features. Any such information 
leak will lead to an overly optimistic estimate of future prediction performance. While 
this rule implicitly prohibits use of simple resubstitution as a method of error estimation, 
the 632+ bootstrap method is a notable exception to the rule. Separation of feature 
selection from training and testing are a major theme of the FDA MAQC-phase II work, 
which I have contributed to, and which is currently under journal review. All work in this 
dissertation strictly adheres to the above-described policies of “honest” cross-validation. 
Quantum Dot Immunohistochemistry 
Biomarkers can be identified, either by applying the previously mentioned 
machine learning techniques to high-throughput discovery technologies such as the 
microarray, or by searching the existing literature for well-established markers, such as 
ER, PR and HER2/neu for breast cancer. HER2/neu in particular, represents a good 
example of clinically-relevant molecular classification of tumors. Patients who 
overexpress HER2/neu can been treated with Trastuzumab, a recombinant monoclonal 
antibody against HER2/neu, in order to increase life expectancy [70]. Protein expression 
for this type of analysis is typically measured semi-quantitatively by a pathologist 
manually scoring the results of immunohistochemical (IHC) staining for the protein of 
interest. 
 To achieve a clinically relevant molecular profile for an unknown subtype of a 
less well studied disease, such as Renal Cell Carcinoma (RCC), a more reliable, and thus 
quantitative, technique than traditional IHC is required. Because of the complexity of 
RCC, and the multiple subtypes to be separated, is expected that a single marker will not 
be sufficient for accurate classification. Instead, it will be necessary to monitor the 
expression of a small panel of markers to build a proper classification rule. Because of 
this constraint, methods which can measure multiple markers simultaneously will be 
favored. Thus, traditional IHC, which measures only one protein’s expression at a time, 
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will not be sufficient for building an accurate classifier, given the limited supply of tissue 
sample in an actual clinical setting. Protein expression in this study will instead be 
measured in clinical samples by staining with multiplexed Quantum Dot (QD) panels. 
QDs have been chosen as the reporter agent due to their ability to be multiplexed and 
their potential to be quantified [71-75].  
 Even with these promising pioneering studies, issues still remain that hold back 
the use of multiplexed QDs in a clinical setting as a quantitative tool. Much like the case 
with microarrays, there is a need for a similar application of quality control and 
computation to improve the reliability and repeatability of QD-IHC to the point where it 
may be used in a clinical setting. These issues are discussed here, and in chapter 5. 
 Multiplexed QD-IHC assays have been developed in a number of labs using direct 
primary antibody-QD (Ab-QD) conjugation [75-77]. Such studies are questionably 
quantitative, due to lack of large-scale reproducibility of custom Ab-QD conjugation, 
making translation to a clinical setting doubtful. A more translational protocol would 
instead use widely available commercial QDs, commercial antibodies, and simple 
chemistry. One such alternative approach, using primary antibody staining and biotin-
streptavidin coupling to QDs in solution, has been achieved, but such protocols are not 
yet suitable for more than 2 markers [78]. Yet another approach involves use of a primary 
antibody stain followed by application of commercial QD-secondary antibody conjugates 
[75]. While this protocol is a promising candidate for clinical translation, multiplexing 
beyond 2 QDs relies on further optimization to reduce antibody cross-reactivity [74]. 
Quantification of protein using QDs relies on the assumption that the QDs 
actually attach to their intended targets. The basic scheme for a 4-plex QD stain using 
commercially available reagents is Figure 5. In this scheme, four different QDs are 
intended for four different protein targets. Problems arise with this protocol whenever 
primary antibodies added in step 1 are not completely saturated by the secondary-QD 
conjugates added in step 2. In such a situation, secondary-QD conjugates added in step 4 
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may errantly bind to primary antibodies from step 1 as well as their intended targets from 
step 3. Figure 7 shows a cartoon of this effect. This antibody cross-reactivity has been 
identified previously in literature as a serious obstacle to QD-IHC becoming useful [74]. 
Unsaturated primary antibody could occur due to any of: (1) Insufficient concentrations 
of QD-secondary conjugates in step 2, (2) Insufficient incubation time in step 2 to cause 
saturation, (3) Disassociation of primary and secondary antibodies during the subsequent 
washing and staining procedures between step 2 and 4, or (4) Other forces i.e. QD-
antibody-valency effects which may cause one QD-secondary to displace another.
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Figure 5: Multiplexed Immunostaining Workflow.  
Step 1 and 3 are addition of primary antibodies, Steps 2 and 4 are the addition of QD 
conjugated secondary antibodies and step 5 is nuclear counterstain with DAPI. A 4-plex 
procedure is depicted, but Steps 3 and 4 may be repeated with different targets and QDs 




If the scenario depicted in Figure 6 were to occur, it would mean the presumption 
of antigen C in tissue locations which express antigen A. Importantly, this effect does not 
work in reverse. For example, QD565 does not bind to antigen C because no primary 
rabbit anti-C antibodies are present when QD565-anti-rabbit is introduced. First and 
foremost, such antibody cross reactivity should be avoided on a chemical and procedural 
level by minimizing the four previously mentioned pitfalls. In the absence of perfect 
staining protocols, software solutions, such as those outlined in chapter 5, are an 
attractive alternative for achieving reliability [15]. 
Unmixing of QD signals from tissue autofluorescence is another problem which 
leads to low sensitivity and quantitative accuracy in QD-IHC analysis of tissue sections 
[74, 76]. Some progress has been made to increase the signal to background ratio using 
the unique properties of QD i.e. long emission half-life [79], or photostabillity [75, 80]. 
Separation of QD from autofluorescent background has been claimed [81, 82], but the 
evidence supporting these claims is minimal, and methods to achieve these results remain 
a trade secret. Our own results discussed in Chapter 4 suggest that autofluorescence is a 





















Figure 6: Undesirable Signal Crosstalk.  
This cartoon illustrates a scenario where QD655 signal will be present at antigen A as 
well as antigen C. This occurs if there is unsaturated or unblocked primary anti-A 




Structure of Dissertation 
 Motivated by the existing questions behind the reproducibility and reliability of 
microarray and QD-IHC data, as well as by the need for developing more reliable clinical 
tests, I have divided this dissertation into three specific aims: 
Specific Aim 1: To develop a comprehensive microarray quality control algorithm to 
minimize the effect of common sources of noise on gene expression calculation 
Specific Aim 2: To investigate the effect of microarray noise and quality control on the 
reproducibility of gene biomarker discovery  
Specific Aim 3: To discover and validate novel clinical gene and protein biomarkers for 
cancer diagnostics. 
Figure 7 summarizes the key areas where this dissertation improves the workflow 
for translating microarray-based biomarker discovery. As part of the proposed 
methodology for Specific Aim 1, algorithms were developed for microarray Chip Artifact 
Detection, Artifact Aware Probe Normalization, and Artifact Aware Expression 
calculation. These all serve to increase the reliability of gene expression, which was 
investigated as part of Specific Aim 2. To achieve Specific Aim 3, the Translational 
Bioinformatics Pipeline was executed for a case study in Renal Cell Carcinoma (RCC). 
The final result of this work represents a step towards quantitative, biomarker-based 




Figure 7: Expected Contribution to the Translational Bioinformatics Workflow.  
Purple items represent data, blue item represent data processing steps, and yellow items 
are expected areas of contribution of this thesis work to the pipeline. 
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Chapter 2, Microarray Quality Control, addresses specific aim 1, and describes 
the proposed microarray quality control system, caCORRECT. New algorithms are given 
for microarray chip artifact detection, artifact aware probe normalization, and artifact 
aware expression calculation. Chapter 2 gives detailed procedural descriptions of the 
caCORRECT method, as well as theoretical justifications for the selected approach. In 
chapter 2, illustrative examples are used to highlight pitfalls of existing methods which 
are overcome by caCORRECT.  
Chapter 3, Quality Control Validation, addresses specific aim 2 by sharing the 
results of a series of validation experiments that aim to justify inclusion of caCORRECT 
in to existing workflows. Results show: (1) that previously published biomarker 
discovery is sometimes correlated or anti-correlated with the presence of chip artifacts, 
(2) that caCORRECT may be used to increase the reproducibility of biomarker selection 
during cross-validation, (3) caCORRECT increases the accuracy of existing gene 
expression calculation methods in the presence of artifacts, and (4) That biomarkers 
selected from caCORRECT-processed data have a better chance of validation on external 
samples. 
Chapter 4, Development of a Biomarker Based Diagnosis, shares the results of 
biomarker discovery, aided by caCORRECT, using a case study of Renal Cell Carcinoma 
(RCC) clinical samples. Biomarkers are first selected from microarray data, and then 
validated with quantitative RT-PCR and quantum dot immunohistochemistry (QD-IHC). 
Results suggest that a panel of two markers, NNMT and PRKAB1, can be used in tandem 
to create an extremely high accuracy (100%, n = 24) RT-PCR based classification system 
for Clear Cell versus Chromophobe RCC. 
Chapter 5, Towards a Quantitative Quantum Dot Methodology, discusses 
progress made towards the next logical step in this work—a quantitative multiplexed 
protein-based tissue assay using QDs as reporter molecules. A survey of current issues is 
given, including QD source separation, characterization of tissue autofluorescence, 
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differences between QDs, antibody cross-reactivity, and chromatic aberration. For each 
of these issues, a future outlook is given and the latest work done to address the problem 
is detailed. 
Chapter 6 provides concluding remarks, and highlights concrete deliverables that 
arose as a result of this dissertation. Finally, an outlook on future work in the field of 
quality control for biomedical informatics is presented. 
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CHAPTER 2 
MICROARRAY QUALITY CONTROL 
 The first specific aim of this dissertation is to develop a comprehensive 
microarray processing algorithm to minimize the effect of common sources of noise on 
gene expression calculation. Novel contributions include the methods for artifact 
identification, as well as the concept of artifact-aware normalization and artifact-aware 
gene expression calculations. Much of the information in this section is an extension or 
reproduction of the original paper describing caCORRECT which was published in the 
Annals of Biomedical Engineering [11]. 
caCORRECT Methodology 
 The proposed microarray processing algorithm is called caCORRECT, which is 
short for “chip artifact correction.” The general workflow for caCORRECT is shown in 
Figure 8. caCORRECT operates on probe-level data from any Affymetrix platform 
microarray and is available for use through a web-interface at cacorrect.bme.gatech.edu. 
The first step in the caCORRECT algorithm is to normalize each microarray intensity 
profile to remove global chip intensity biases which may arise due to variation in RNA 
extraction, amplification, and hybridization procedures. This normalized data is then 
processed through four rounds of variance calculation, artifact identification, and artifact-
aware normalization. After artifacts have been identified, the probe data are fit to 
caCORRECT’s gene expression model, which ignores artifact data. Here, the phrase 
“gene expression model” is used as a more flexible synonym of the industry term “probe 
summarization,” which belies the two-way relationship between probe data and gene 
expression. Some readers may be more familiar with this process being called “chip 
normalization”, which is a misnomer that we will avoid altogether. 
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 After fitting data to the gene expression model, users are then given three options: 
(1) to directly use the gene expression output from caCORRECT’s gene expression 
model, (2) to replace artifact probe data with values imputed using caCORRECT’s gene 
expression model and then send the resulting partially-imputed probe data to an existing 
third party method of probe summarization, such as RMA, or MAS5.0, or (3) to send 
caCORRECT’s outlier information as a direct input to a third party probe summarization 
method. This third option is not always available, because it relies on the third party 
software’s ability to take in and use such artifact information appropriately. Each of these 




Figure 8: caCORRECT Workflow.   
Gold items represent data, while blue items represent data processing steps. The grey 
region indicates portions of the workflow unique to caCORRECT. These steps are 
skipped in existing protocols. Raw chip data are the inputs to the system, and both clean 




 The cornerstone of caCORRECT’s outlier detection is the concept of variance 
scoring, which produces a value indicating each probe’s tendency to be an outlier. 
Calculation of this score is similar to conducting a t-test to determine whether or not 
observed probe intensity for a given chip belongs to the observed null distribution of 
probe intensities for all other chips in the dataset. A key feature of caCORRECT is that 
this null distribution is updated during each round to include the most up-to-date probe 
expression data and to ignore any probes on other chips which themselves have been 
flagged as artifacts. Because of this dynamic updating, it is possible to identify subtle 
artifacts or pardon false artifacts which may have been misdiagnosed initially. 
To estimate this null distribution for each probe on chip j, data from the other 
chips are analyzed. First, an artifact weighted mean, µj, is calculated by using the 
expression values, xi, from other chips, (i ≠ j), in the dataset, and an artifact attenuation 
factor, αi. As a default, the attenuation factor equals 1 for spots that have not been 
identified as artifactual, and 0 for spots that have been identified as artifactual. After this 
weighted mean is calculated, an artifact weighted deviation score, σj, is calculated in a 
similar manner. These two statistics, µj and σj, form a description of the null distribution 
against which xj is to be compared. The final variance statistic, zj, for a location is then 
calculated as the difference between the observed intensity, xj, and the weighted mean, µj, 









































































The result of this calculation is a variance statistic, z, for each spot on each chip in 
the study. A high magnitude z indicates artifactual tendency, while a low magnitude z 
suggests that the spot is to be trusted. Note that a high magnitude score could also be a 
result of biologically relevant gene expression, but those cases will be generally ignored 
during the artifact identification procedure described in the next section. A nonlinear 
scaling procedure is then applied to each z to yield h, which is a score between 0 and 1 
that has been adjusted for the number of chips in the dataset, and is similar, but not 
equivalent to 1 minus a p-value. This adjustment is made to provide consistent 




















In the above formula, n is a scaling factor equal to the ratio of the p=0.5 critical 
point in the student’s t distribution with degrees of freedom equal to one less than the 
number of chips, or ∑
≠ ji
iα , used in the calculation of zj, to the p=0.5 critical point in the 
Gaussian distribution. Since the number n increases with decreasing degrees of freedom, 
this scaling factor helps ensure that successive rounds of caCORRECT do not 
progressively and indefinitely shave off more and more outliers until there is nothing left. 
 42 
This statistic is used as a guideline for identifying regions of chips where artifacts are 
present as discussed in the next section. 
Artifact Segmentation 
 Once the variance statistic, h, has been calculated for each probe on each chip, 
false-color heat maps of h, showing probes in their original spatial layout, are generated 
to display regions of high noise. For a good quality microarray chip, h will represent 
biological variation in RNA expression for the sample. In this case, h will be distributed 
similarly to white noise throughout the chip. More commonly, however, protocols do not 
achieve uniform hybridization due to uneven drying, formation of salt streaks, scratching 
of the microarray surface due to contact with skin or dust, miscalculated hybridization 
times, or failure to control environmental variables such as ozone [83]. All of these most 
common mistakes result in visible localized regions of large h (artifacts) on the heat map. 
Previous versions of caCORRECT included a manual artifact identification tool, 
but this has been discontinued in favor of an automated batch removal process. Aside 
from being generally faster and less complicated than manual artifact removal, batch 
mode has the added advantage of reproducibility. During batch removal, a specialized 
sliding window method is used to flag probes that meet two conditions: (1) they exist in 
regions of other high-scoring probes, and (2) they have high scores themselves. These 
two conditions ensure that most of the obvious artifacts are caught, but that most of the 
naturally occurring biological variance goes unselected. This automated artifact 
identification is generally conservative compared to manual artifact identification 
involving human interpretation of heat maps. Conservative artifact identification is ideal 
when one considers that caCORRECT is designed to identify spatial artifacts upstream in 
order to supplement the model-based outlier detection employed by most probe 
summarization methods. To remove any global chip effects that arise from sample 
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preparation or amplification, normalization is performed as described in the following 
section. Figure 9 highlights sample results of artifact segmentation. 
Because the intended platform for caCORRECT is a web service, artifact 
identification has been streamlined for speed and memory efficiency. More 
computationally intense methods such as active contours, PDE-based methods, or shape 
matching have been excluded in favor of a quick marching window algorithm that seems 
to work well for a wide range of data. 
 
  
Figure 9: Sample Heat Map and Artifact Segmentation Results.  
The left image shows a heat map generated by caCORRECT. The right image shows 
areas in black where the batch mode of caCORRECT has determined artifacts are 
present.  
 
Artifact Aware Normalization 
 Quantile normalization, as described in [84] and recommended by the latest FDA 
MAQC results[1], reduces bias between microarray samples by forcing the intensity 
distribution of each chip to be identical. The critical assumption behind quantile 
normalization is that for genome-wide studies such as those involving microarrays, the 
number of genes which are invariant to the experimental variables far outnumbers the 
number of those that are dependent on experimental variables (biomarkers).  A set of n 
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distributions is said to be from the same family of distributions (i.e. normal, uniform) if a 
scatter plot in n dimensions of the quantiles from n chips results in a straight line. From 
this it follows that projecting each quantile onto the unit diagonal vector will transform 
all distributions to one identical distribution. This method is generally appropriate for the 
microarray problem, where the distributions are poorly defined, and parametric methods 
break down. The power of quantile normalization comes with a major caveat: if the chips 
are not from the same distribution, the algorithm will indiscriminately warp the 
distributions to be the same and proceed as if nothing bad happened. Fortunately, it is a 
reasonable assumption that high-quality microarray data from a single source on a single 
platform will follow the same distribution. Unfortunately, this high quality assumption is 
not valid for much real-world data, where chip artifacts can significantly alter the 
distribution of intensities on a chip. One bad chip ends up warping the others when 
quantile normalization is performed, thus compromising the reproducibility of the results. 
A way to alleviate this problem is to identify artifacts before quantile normalization, and 
set them aside temporarily. In theory, perfect knowledge of artifacts would allow for 
perfect correction. This process is called “artifact-aware quantile normalization.” In the 
batch mode of caCORRECT, four iterations of normalization and artifact identification 
are performed in order to achieve a near steady-state result (data not shown). 
 To illustrate the invasive effect that artifacts can have on a dataset when quantile 
normalization is performed, synthetic microarray data were generated in the following 
manner: 
1) Six high-quality chips from the Schultz et al. dataset were chosen, one of which 
was set aside to receive artifacts. 
2) One third of the selected chip was modified by a multiplicative factor of 0.5, 
representing a low-intensity artifact. 
3) A different third of the selected chip was modified by a multiplicative factor of 
10, representing a high-intensity artifact. 
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These six chips were then processed using caCORRECT, and the probe intensities were 
monitored at the end of each normalization round. 
 Figure 10 demonstrates the difference between standard quantile normalization 
and the proposed artifact-aware normalization using artifacts identified with 
caCORRECT’s iterative batch mode on the modified Schuetz et al. dataset [85]. As can 
be seen in the raw intensities (top panel), the induced artifacts (leftmost and rightmost 
modes in the blue histogram) caused a differently-shaped distribution than that of the rest 
of the chips in the dataset. Once the first round of standard quantile normalization was 
performed (middle panel), the ‘warping’ of the non-artifacts was clear by the way that 
each of the distributions were now identically and incorrectly trimodal. After four rounds 
of artifact-aware normalization were performed (bottom panel), each of the good chips 
returned to its natural distribution (chips 1 through 4 are obscured behind the pink line, 
chip 6, since they all have similar distributions). For the (blue) chip with the artifacts, the 
artifact modes were still clear, but now the remaining non-artifactual data on the chip had 





Figure 10: Undesirable Effects of Standard Quantile Normalization and Correction with 
Artifact-Aware Quantile Normalization Using caCORRECT.  
The top image shows the distribution of probe intensities of six microarray chips. The 
middle image shows the distribution of all chips after quantile normalization. The bottom 
panel shows the distributions of all six chips after artifact-aware quantile normalization. 
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Treatment of Identified Artifacts 
Integration with Existing Workflow 
The general workflow for microarray probe summarization is to input Affymetrix 
probe-level data and receive gene expression data as an output. This process is analogous 
to modeling many observations (probe data) of one quantity (gene expression). 
caCORRECT allows for three different strategies with respect to this general workflow 
(See Figure 11). The first integration option is to have caCORRECT directly summarize 
probe data using its own model of gene expression. The second option is to have 
caCORRECT overwrite data considered to be part of an artifact and then export this 
‘clean’ dataset to a third party method of probe summarization. The third option is to feed 
caCORRECT’s artifact information into existing third party probe summarization 
methods. Note that the third option may not be possible with all third party software. 
To help users interpret results, client software such as RMAExpress or 
caCORRECT outputs a residual image similar to caCORRECT’s variance score heat 
maps which show the residuals between every probe intensity and the model. Close 
interpretation of these residuals can reveal how well a particular model fits the data. 
While the latest version of caCORRECT uses model-based imputation, old versions of 
caCORRECT simply replaced artifact data for a given probe with the median of that 
probe’s intensity in all other chips of the data set. An example of what such artifact 
replacement does to the residuals of the RMA model for a real chip is shown in Figure 
12. From the figure, it can be seen that median replacement fits the RMA gene expression 
model fairly well, and that caCORRECT generally does a good job of finding and 
correcting compact artifacts. Diffuse artifacts, like the one in the upper right hand corner 






Figure 11: Options for caCORRECT Integration with Third Party Software.  
Gold items represent data, while blue items represent data processing steps. White ovals 
show third party software components. 
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Figure 12: Relationship between caCORRECT and Gene Expression Model Residuals.  
The top left image shows the heat map generated for an actual microarray chip by 
caCORRECT, and the results of artifact detection are shown in black in the upper right 
image. The bottom left image shows the model residuals (positive in red, negative in 
blue, zero in white) before caCORRECT, and the bottom right shows residuals after 
artifact data have been replaced with median values (from an older version of 
caCORRECT). Note that most of the small speckle artifacts are corrected nicely while the 
more complex artifact is less straightforward. 
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Modern Gene Expression Model 
The current version of caCORRECT uses a model relating probe intensity to gene 
expression that is mathematically similar to the model used by RMA and others [5, 6, 
39]. In this scheme, the artifact-flagged probe-level data is replaced with the best-fit-
estimate for that probe given the model and data from non-artifactual probes on all of the 
chips being processed. To understand how observed probe intensities relate to estimates 
of gene expression, one must first understand the binding kinetics occurring at the 
microarray surface. 
In a simple model, all copies of a given sequence of the sample cDNA can exist in 
any one of two states during its application to a microarray: (1) free floating in solution: 
“unbound” or (2) “bound” to its complimentary strand on the microarray surface (Refer 
back to Figure 4 for an illustration of this). In an ideal scenario with thin layers of liquid, 
and abundant binging locations on the chip surface, the transition from the bound to the 










In reality, the complimentary binding of two DNA strands is a highly complex 
process which is not a simple first-order kinetic event, but we will use this simplifying 
assumption for now, because the downstream conclusion does not rely on this as a fact. 
After the array has had time to incubate and reach equilibrium, the amount of bound and 









There is one notable exception to this formula, which is in the case of an 
extremely large concentration of sample cDNA. In this case, the target sites on the array 
can become saturated, and the previous two equations no longer hold. For microarrays, 
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which measure bound cDNA via fluorescence, the light detector which quantifies the 
fluorescence will saturate before this point. Detector saturation is easily noticeable, and 
data which is saturated should be ignored when possible.  The “total” cDNA present, 
which is the quantity ultimately being measured, is the sum total of the bound and 
unbound cDNA. Using this fact, and some algebraic manipulation, reveals that the 



















Because of the binding specificity of DNA, the value of kon will be much larger 
than koff for complimentary sequences. The opposite will be true for non-matching 
sequences, and an intermediate balance will be the case for sequences off by only one 
base pair, such as the so-called mismatch sequences. For our purposes, we assume that 
(1) the fraction relating total cDNA to bound cDNA exists for every target sequence and 
it’s complementary probe sequence, (2) another, smaller, fraction exists for every target 
sequence and it’s nearly-complementary mismatch probe sequence, and (3) that this 
fraction is zero for all other probe sequences on the array. Note that Affymetrix arrays are 
designed to maintain this third assumption and include steps to avoid redundant or 
overlapping sequences, which may invalidate the assumption. 
There are at least two other scaling factors besides this binding fraction which are 
used to relate the original concentration of RNA in the sample to the observed intensity 
on the microarray. First, the amplification step, which uses the original RNA from the 
biological sample to create many fluorescent cDNA copies, introduces a multiplicative 
gain, g1. The amount of amplified cDNA is then attenuated by the previously mentioned 
binding fraction, g2, to give the amount of cDNA bound. Finally, the process of 
fluorescence imaging introduces another multiplicative gain, g3, relating the amount of 
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bound cDNA to the fluorescence intensity. These three factors can be lumped together to 
give an overall probe affinity factor, a. 
 
cefluorescengggRNA ≈321 ***][  (2.9) 
 
aggg =321 **  (2.10) 
In caCORRECT, observed microarray intensity values are modeled as a 
multiplicative combination of target RNA abundance (gene expression) and probe-
specific effect (probe affinity). The model is given as: 
 jpbpbjpjpb
ax ,,,,,, εθ +=  (2.11) 
where jpbx ,,  is the observed intensity for the b
th 
probe in the p
th
 probe set on the j
th 
chip, 
jp,θ  is the gene expression term corresponding to initial RNA concentration, pba ,  is the 
lumped probe affinity term, and jpb ,,ε is the additive error term which accounts for both 
instrument noise as well as nonspecific binding. For a detailed discussion of the noise 
model, and an explanation of the solution to this gene expression model, refer to 
Appendix A. The model is both regressive and generative in the sense that it may be used 
to estimate the parameters jp,θ and pba , from a given dataset, and it may also be used to 
impute synthetic intensity data jpbx ,,ˆ  given a set of jp,θ and pba , . As the last step of 
caCORRECT, all probe data determined to be part of an artifact is replaced by this 
imputed intensity value, jpbx ,,ˆ . 
Applying in the Gene Expression Model 
The Affymetrix microarray is redundant, in that there are usually 40+ probes on a 
single array (20+ PM, 20+ MM), that target a single gene. Solving the model equations is 
still underspecified for a single chip; i.e. there are 40 observed intensities (40 equations), 
but 40 probe affinities and 1 gene expression term to estimate (41 unknowns). Adding a 
second chip to the batch doubles the number of equations but only adds one new 
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unknown (a gene expression to estimate) since probe affinities are a sequence and 
protocol specific value that should be conserved across chips in a single dataset. In the 
case of more than one chip, the model becomes increasingly over specified, and it can be 
solved using standard least-squared-error techniques (See appendix A). This over 
specification allows caCORRECT and other models the option to throw out large 
amounts of data and still reliably estimate gene expression. The benefit that caCORRECT 
provides is improved knowledge of which data to discard.  
Figure 13 represents a case study using residual images to compare how 
caCORRECT and RMA react to the presence of a scratch on a chip from the West dataset  
[86] (also shown in Figure 9). The layout of the Hu-6800 chip is such that all probes 
which make up a single probe set are arranged in contiguous regions on the microarray 
(See “retired format” in Figure 3). This property allows for easier visual interpretation of 
residual images, and is why this dataset was chosen for this case study. The leftmost 
panel of Figure 13 shows the residuals produced by the caCORRECT model without any 
attempt to identify artifacts or ignore outliers. The blue (negative residual) regions which 
surround the main red (positive residual) scratch demonstrate the ambiguity which arises 
when outliers are present. The dilemma for the modeling algorithm is that it doesn’t 
know if the red data are artificially high, or if the blue data are artificially low. As a 
result, the optimal uninformed model splits the difference, and assumes that all data 
points are slightly wrong. In contrast to the uninformed model, this disambiguation is 
easily made by caCORRECT, which identifies the actual scratched region as bad, and the 
surrounding data as good by h score alone (see the heat map of h in Figure 9). 
caCORRECT’s segmentation algorithm further disambiguates the scratch from the 
background. The residuals which are calculated after caCORRECT has identified 
artifacts are shown in the middle panel of Figure 13. At this step, it is clear by the white 
region surrounding the scratch that caCORRECT has successfully disambiguated the 
decision, deciding that the high-intensity data of the scratch are to be ignored, and the 
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resulting model uses only the remaining probe data to estimate gene expression. The 
rightmost panel of Figure 13 shows the final result produced by RMAExpress without 
any intervention by caCORRECT. RMA includes its own outlier detection, but RMA’s 
detection is not informed by spatial location, and thus cannot recognize a scratch as such. 
The figure suggests that RMA does a fair job of disambiguating the scratch from the 
surrounding data, but some areas of blue still exist, suggesting that the gene expression 
values for these probe sets have been overestimated. These problems have been almost 
completely avoided by caCORRECT. 
Another perspective on this same case study is shown in Figure 14, which shows 
the result of model fitting before and after caCORRECT quality control to identify 
artifacts. The data from four probes are displayed for each of the 49 chips in this dataset. 
In both cases, the chip with the highest gene expression is the one discussed earlier and 
shown in Figure 13. Regression lines for each probe are also provided for reference. 
Points appearing above their line give a positive residual, while those below are 
considered to have a negative residual. Without proper knowledge that the cyan-colored 
probe on the scratched chip is part of an artifact, the best-fit model estimates log gene 
expression for the questionable chip near 8.3. With caCORRECT-generated knowledge, 
the log gene expression is estimated nearer to 7.4, a change of an entire order of 
magnitude. The proximity of the remaining data to their respective regression lines is 
another indication that caCORRECT chose correctly.
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Figure 13: Effect of Scratch Artifact and Removal on Residual Images.  
Red color indicates positive residuals, blue color indicates negative residuals, and white 
indicates good fit to the model. Blue color surrounding the red scratch reveals poor model 
fit to the data which is likely to cause an overestimate of gene expression for these 
probes. (left) Initial residual produced by caCORRECT. (middle) Residual produced by 
caCORRECT after artifact flagging. (right) Residual produced by RMA. The figure 
indicates that caCORRECT is more robust to this scratch than RMA is. The reduced 
resolution for the right panel is explained by the way that RMA handles pairs of perfect 




Figure 14: Effect of Scratch Artifact and Removal on Gene Expression Estimate.  
Four probe sequences for this probe set are shown, each with its own color. Lines 
represent the best-fit line relating probe expression to gene expression. Data from the 




In this chapter, we have described the methodology of caCORRECT, and 
discussed many theoretical and practical shortcomings of existing methods of outlier 
detection and global chip normalization.   
Using a small 6-chip dataset as an illustrative case study, we have shown how the 
existing gold-standard normalization method, quantile normalization, can have a severe 
negative impact on the data quality it attempts to improve. Furthermore, we provide a 
method whereby this warping phenomenon can be almost completely avoided, without 
compromising the original intent of the quantile normalization algorithm. 
We also demonstrate, using the example of a prominent scratch on a real clinical 
microarray, the superior artifact finding ability of caCORRECT as compared to existing 
model-based methods such as RMA. While existing technologies, including robust 
modern chip layouts and robust statistical outlier detection algorithms, do perform 
satisfactorily enough for microarrays to be considered a clinically viable technology, 
caCORRECT represents a significant technical improvement in microarray data analysis. 
The next chapter discusses further empirical validations of caCORRECT. 
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CHAPTER 3 
QUALITY CONTROL VALIDATION 
 The second specific aim of this dissertation is to investigate the effect of 
microarray noise and quality control on the reproducibility of gene biomarker discovery. 
Direct comparisons of caCORRECT to existing methods are difficult because, with each 
of the methods mentioned earlier, noise removal and gene expression calculation are 
either inseparable or not integrated. This therefore limits experimentation to the form of 
comparing A) using caCORRECT and B) not using caCORRECT before proceeding to 
gene expression calculation by the most widely accepted methods, RMA and MAS5.0. In 
this chapter, a series of experiments are conducted to showcase the various ways in which 
caCORRECT can improve microarray results. Some of the results in this section are 
reproductions of my contributions to publications in the Annals of Biomedical 
Engineering [11] and Life Science Systems and Applications Workshop [12]. 
Overlap of Presumed Biomarkers and Chip Artifacts 
 This first investigation was actually more of a justification than a validation of the 
use of caCORRECT. Before attempting to improve any results with caCORRECT, we 
first made sure that the problem that caCORRECT addresses (chip artifacts) was linked 
to the problem that we wish to address with caCORRECT (successful translation and 
reproducibility of results). Accordingly, in this section, we answer the question: “Is there 
a relationship between published microarray results in literature and chip artifacts?” To 
answer this question, we conducted a survey of existing high-impact publications which 
had also provided access to probe intensity data. In these publications, we investigated 
whether their proposed biomarkers could be correlated with to chip artifacts. Although 
correlation does not imply causation, it at least allows the possibility that solving the 
problem of microarray artifacts may have an affect on biomarker selection. 
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Methods 
 To measure if there is a relationship between published biomarkers (identified 
before the existence of caCORRECT) and artifacts flagged by caCORRECT, overlap was 
observed between these two events using a combination of literature mining and post-hoc 
analysis. Previously identified biomarkers from third-party analysis were manually mined 
from the literature and mapped back to their spatial locations on the chip. These locations 
were then overlaid with the location of artifacts discovered during the QC process using 
the binary masks produced by caCORRECT. To produce a whole dataset mask, showing 
the number of artifacts found at each probe throughout the entire dataset, the N artifacts 
masks from each of the N chips were overlaid (summed together). The final result 
describes the locations and number of artifacts as well as the locations of biomarkers.  
 In order to analyze this data quantitatively, a comparison was made between the 
number of artifacts found on biomarker probes, and the number of artifacts found on all 
other probes on the chip. First, two discrete probability density functions were estimated: 
one for the set of biomarker probes, fb, and another for the rest of the probes on the chip, 
fr. These density functions were estimated directly from the observed overlap frequencies 
and represent the set of probabilities (fb(i) or fr(i)) of encountering i artifacts at a random 
probe. After the two probability density functions were estimated, they were then 









 The distribution of this dissimilarity statistic is not well defined, and varies based 
on the number of biomarkers as well as the artifact coverage of the dataset. In order to 
estimate the significance of any observed dissimilarity, an ad-hoc null distribution of 
dissimilarity was generated for each new dataset by permuting the class labels for the 
biomarker status of each probe many times. The distribution of the dissimilarity measure 
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across the permutations serves as a basis for estimating the significance of the dataset’s 
true dissimilarity value. Highly significant dissimilarities are an indication that the 
association between biomarkers and artifacts for a dataset is nonrandom. 
Results 
 Visualization of chip regions with high numbers of artifacts can reveal patterns of 
possible chip mishandling. Figure 15 shows a visualization of all of the artifacts found by 
caCORRECT in the dataset published by Shipp et al. overlaid with the locations of 
biomarkers claimed by the original authors [88]. The first observation to be made from 
this visualization is the remarkable preference of artifacts to occur on the right hand side 
of the array. Without detailed observations of chip operators, it would be difficult to draw 
strong conclusions as to the origins of these errors, but it is easy to image a scenario 
where a novice operator has a tendency to touch the array surface with their right thumb 




Figure 15: Overlap of Active Artifact Regions with Biomarkers.  
Artifacts seem to be concentrated on the right hand side of the chip. Biomarkers can be 




Visualizing and quantifying the overlap of biomarkers and artifacts is a critical 
step in forming conclusions about the quality of microarray data and the reliability of  
biomarker selection. However, interpreting the results of these analyses can be somewhat 
controversial. Figure 16 shows analysis results derived from three manuscripts and their 
corresponding datasets, which exhibit various degrees of overlap between biomarkers and 
artifacts. Three scenarios are evident. 
 In the first scenario, as seen in the Schuetz et al. dataset [85], genes of interest 
were uniformly and independently distributed with respect to outlier probes. This 
suggests that outlier data were unable to bias the gene selection process. However, upon 
further review, one might question the validity of these supposed biomarkers which were 
identified based on noisy data, in terms of both false positives as well as false negatives.  
 In the second scenario, as seen with the West et al. dataset [86], the genes of 
interest were located preferentially in the less noisy portions of the microarray. One 
might conclude that these biomarkers are ‘better’ because they have been derived from 
less noisy data. However, many ‘good’ biomarkers may have been excluded simply 
because they are hiding in noisy regions of the chip. 
 The third scenario, from Shipp et al. [88],  when biomarkers co-occurred with 
outlier probes, is not conclusively bad. It could be that the detection of outlier probes was 
biased by the true differential expression of a biomarker and not the reverse. Proper 
interpretation of these overlap results requires careful examination of the exact methods 
of quality control, outlier detection, and biomarker detection and how they may affect 
each other. Such thorough analysis is impractical for even the most carefully written 
manuscripts, because of generally irreproducible methodologies. Due to this limitation, 




Figure 16: Selected Empirical Probability Density Functions.  
Blue represents genes of interest and red represents genes not of interest. (top) The Shipp 
et al. Diffuse B-cell Lymphoma dataset [88] showed a significant (p < 0.001) trend of co-
localization. (bottom right) The Schuetz et al. renal dataset [85] showed no significant 
overlap (p > 0.05). (bottom left) The West et al. Breast Cancer dataset [86] showed a 
significant (p < 0.001) trend against co-localization. This figure has been modified from 
its original version, presented at the Life Science Systems and Applications 
Workshop[12]. 
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caCORRECT and Reproducibility of Feature Ranking 
A list of biomarkers is the common result of a microarray experiment, and thus is 
the common target of many studies attempting or commenting on reproduction of 
microarray experimentation [22, 25, 26, 29, 89, 90]. A ranked list is a special case of 
biomarker selection that lends itself to more precise comparison than unranked lists. This 
section investigates how caCORRECT influenced the repeatability of ranked lists 
generated from two halves of a large microarray dataset. 
Methods 
 To determine the ranked gene list for each dataset, one-dimensional linear 
Support Vector Machines (SVM) was used. SVM was chosen because of its ability to 
generalize well in the face of noise, and its stable error estimation, which make it ideal 
for selecting ranked lists of candidate biomarkers. The SVM classifier uses a Gaussian 
bolstering kernel with a bolstering radius of 1.4826 and 100,000 points of Monte Carlo 
integration for error estimation. More information on the implementation of SVM, its 
application to microarray study, and sensitivity to quality control, can be found here [8, 9, 
64, 91, 92]. The classification error output by the SVM was used as a basis to rank each 
gene.  
 To measure caCORRECT’s effect on the reproducibility of microarray 
experimental conclusions, ranked lists of biomarkers were compared from two 
independent datasets obtained by splitting one large dataset in to two halves. This split 
ensured isolation of confounding variables such as lab technique or array platform. The 
goal was to find little change between ranked gene lists of two different datasets—
indicating reproducibility of findings. To create these independent datasets, the 49 chip 
dataset published by Huang et al. [93] was randomly split into two non-overlapping data 
subsets. In this way, one large 24v25 dataset was split into subsets of 12v12 and 12v13. 
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Each of these subsets was then used as input for a support vector machines gene ranking 
routine twice; once without any QC, and once after experiencing artifact flagging and 
data replacement from caCORRECT. RMAExpress was used for all gene expression 
calculations in this study. Figure 17 shows a schematic for this experimental design. 
 The above process produced four different lists of ranked biomarkers. These four 
lists were then compared to each other in pairs to determine reproducibility of findings. 
To compare lists, first, the ranks were transformed to the log2 scale to reflect the decrease 
in marginal discriminatory power with an increase in rank. Any gene which occurred in 
the top 100 of either list was chosen for further analysis. For each of these chosen genes, 
the difference in log2 rank for that gene between the two lists was calculated. The 
distribution of this difference statistic thus describes the similarity of the two ranked lists. 
The entire data-splitting, feature-ranking, and rank-comparing procedure was then 





Figure 17: Illustration of Workflow for Biomarker List Comparison.  
Datasets consisting of probe-level microarray data are shown in light blue, expression 
level microarray data is in red, and ranked lists in orange. The three comparisons made 
here correspond to the results shown later in Figure 18. This figure reproduced from the 
2007 ABME paper [11]. 
 67 
Results 
 Results from the independent splitting of the Huang dataset are summarized in 
Figure 18. It can be seen that using caCORRECT on both halves of the dataset improved 
the reproducibility of ranked gene lists in two ways. First, distribution plots show an 
increase in the number of genes whose rankings did not change more than two-fold; i.e. 
more gene ranks were conserved. Secondly, the mean of rank differences after 
caCORRECT was significantly lower than that obtained without caCORRECT (p<0.05). 
 
Figure 18: Effect of caCORRECT on Similarity of Ranked Gene Lists during Cross 
Validation.  
This figure reproduced from the 2007 ABME paper [11]. 
 
Effect of Applied Artifacts and Preprocessing on Gene Expression  
 With the motivation that there is (sometimes) a link between artifacts and 
biomarkers, and that caCORRECT preprocessing can increase the reproducibility of 
feature lists, we now remove biomarker selection and classification from the pipeline, and 
instead investigate how caCORRECT improves the accuracy of the microarray itself as a 
clinical profiling tool. More precisely, this next investigation quantifies how 
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caCORRECT improves the accuracy of gene expression, which is the driving input to 
both biomarker selection and clinical decision making.  
 Determining the accuracy of a microarray in the traditional sense usually involves 
comparison to other arrays of or  PCR measurements of the same biological samples[1] 
or measurement of known “spike-in” transcripts[5, 46, 59, 94]. Instead of these costly 
methods, we instead chose to compare microarrays to themselves by simulating new 
versions of arrays with applied artifacts. Only high quality arrays were chosen so that 
each array may serve as its own gold-standard. 
Methods 
 In order to quantify the ability of caCORRECT to improve the accuracy of 
microarray gene expression, and thus the reproducibility of array dats, a set of otherwise 
high-quality breast cancer microarray data (selected for quality by the MAQC-II 
Consortium) were altered with a series of randomized synthetic artifacts and then 
processed with caCORRECT. Artifacts were originally generated for the MAQC-II Jones 
et al. study on classifier performance in the face of artifacts, and were created blindly 
with respect to caCORRECT and its developers. 
 Two types of artifacts from Jones et al. were investigated here: (1) the h90 “black 
hole” artifact in which an elliptical region of the microarray had probe intensities lowered 
severely, and (2) the s90 “hot spot” artifact in which an elliptical region of the microarray 
had probe intensities raised severely. Such elliptical artifacts represent one of the two 
most frequently observed artifacts in microarrays. The other type of artifact is more 
diffuse in nature, and tends to appear near the edges or corners of arrays, most likely due 
to fluidics and drying issues. For the Jones et al. study, we were able to use caCORRECT 
to identify and transplant this second type of artifact from actual chips onto the chips in 
the Jones study. We did not, however, use these caCORRECT-generated artifacts in the 
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analysis of caCORRECT’s ability to remove artifacts for the purpose of scientific 
integrity. 
 For each of the Jones-created elliptical artifacts, the orientation and location of the 
artifact region was altered randomly for ten times on each of the 49 chips of the 
validation set designated by the original microarray data suppliers, Hess et al. [95]. For 
each of the 10 altered chips, gene expressions were calculated both before and after 
caCORRECT’s complete artifact detection and value imputation were applied. Each of 
these estimated gene expressions was then compared to the “true” gene expression values 
obtained from the respective original, unaltered chip to yield an error value representing 
the deleterious effect of the artifact on gene expression estimation for each probe set. 
The errors for each probe set (~8000), each chip (49), and each artifact replicate (10) 
were then pooled together to form two distributions of the error function for each of the 
two artifact types: one for unprocessed data, and one for data cleaned with caCORRECT. 
For each chip, gene expression data for all probes were determined using MAS5 in 
Expression Console and the R implementation of RMA.  
Results 
The effect of applied quality insults on gene expression was monitored for two of 
the most popular probe summarization methods: RMA and MAS5.0. The agreement of 
gene expressions before and after induced artifacts is shown in Figure 19. Two 
phenomena are immediately observable:  
First, for the “black hole” artifacts which lower probe intensities on the 
microarray, the MAS5.0 algorithm had the tendency to call many of the genes ‘absent’, 
and report the gene expression abnormally low. caCORRECT was able to almost 
completely reverse this trend, and was generally able to rescue the true gene expression. 
 Second, for the “hot spot” artifacts which raise probe intensities on the 
microarray, the RMA algorithm had the tendency to underestimate gene expression and 
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lose accuracy for the genes most highly expressed in the sample. This was most likely a 
result of the issues related to quantile normalization discussed in Chapter 2. This 
phenomenon also happened to RMA to a lesser extent for the black hole artifacts. The 
robustness to black holes was most likely due to a natural dilution effect caused by the 
relatively large number of low-expression (in many cases, mismatch) probe sets on a 
microarray. Chips processed first with caCORRECT and then with RMA did not seem to 




Figure 19: Scatter plots of Gene Expression after Quality Insult Versus Original Gene 
Expression.  
Data shown are for one representative chip, and all probe sets on the HG-U133A 
platform. Gene Expression is calculated either independently with MAS5 or with RMA 
as part of a batch containing the 81 chips in the training set. caCORRECT normalization 
is performed as part of a batch with the 81 chips of the training set. Units of gene 
expression are on the scale of the natural log of probe intensity. caCORRECT improves 






 For each combination of preprocessing and probe summarization, the root mean 
squared error (RMSE) of the gene expression estimate was calculated by assuming the 
ground truth to be the gene expression obtained from the original unaltered chips. Results 
confirmed the scatter plot evidence, and show that MAS5 performed poorly on the 
subtractive “black hole” artifacts, while RMA performed poorly on the additive “hot 
spot” artifacts. In both cases, preprocessing with caCORRECT was able to reduce the 
effect of the artifacts as seen in a reduction of RMSE. Figure 20 and Table 3 summarize 
these findings in terms of the distribution of RMSE across all probe sets on the chip.  
 
Table 3: Effect of Artifact Type and Preprocessing Procedure on Precision and 
Reproducibility of Gene Expression.  
Shown are the mean values for the curves shown in Figure 20. 





hot spot none MAS5.0 0.31 
hot spot caCORRECT MAS5.0 0.25 
hot spot none RMA 0.32 
hot spot caCORRECT RMA 0.11 
black hole none MAS5.0 0.96 
black hole caCORRECT MAS5.0 0.35 
black hole none RMA 0.38 





Figure 20: Effect of Artifact Type and Preprocessing Procedure on Error of Gene 
Expression Estimation.  
Data shown are for all 49 chips in the validation dataset, and all probe sets on the HG-
U133A platform (composing the histogram bin counts). Root Mean Squared Error is 
calculated for each probe set separately across the 10 Monte Carlo artifacts. RMSE is 
calculated assuming the ground truth to be the gene expression values derived from the 
original, unaltered chips using each respective combination of preprocessing and 
summarization method. Units of gene expression are on the scale of the natural log of 
probe intensity. caCORRECT improves the reproducibility of these chips by reducing 




Clinical Validation Pilot Study 
 The final and most clinically relevant validation of caCORRECT is testing to see 
if caCORRECT has an appreciable affect on the reliability and reproducibility of the 
translational bioinformatics pipeline. This validation began with a PCR pilot study of 
microarray-derived biomarkers that changed status with quality control. 
Methods 
Three separate ranked lists of biomarkers were produced from the RCC 
Microarray data [85] according to Figure 21: (1) before any quality control, (2) after 
processing with caCORRECT, and (3) after removing two chips deemed to be 
unacceptable after processing with caCORRECT. The resulting ranked lists are referred 
to as pre-QC, post-QC (all), and post-QC (trim) lists respectively. All gene expression 
calculations were obtained using the RMA algorithm, using RMAExpress. When using 
RMAExpress, all data were processed using both the quantile normalization and 
background correction features included in the software. Ranked gene lists for each 
dataset we created with one-dimensional linear Support Vector Machines (SVM). The 
SVM classifier uses a Gaussian bolstering kernel with a bolstering radius of 1.4826 and 
100,000 points of Monte Carlo integration for error estimation. The classification error 
output by the SVM is then used as a basis to rank each gene.  
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Figure 21: Workflow for Clinical Pilot Study.  
Three ranked lists are obtained from the single input RCC dataset. 
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Pre-QC and post-QC (trim) biomarker lists were then compared to select sets of 
genes fulfilling the following criteria, also shown in Figure 22: 
Set 1: The gene must be ranked highly in the pre-QC list, and ranked much lower on the 
post-QC (trim) list. This represents a hypothesized false positive. 
Set 2: The gene must be ranked highly in the post-QC (trim) list, and ranked much lower 
on the pre-QC list. This represents a hypothesized false negative. 
Set 3: The gene must be ranked highly in all three lists. This represents a hypothesized 
True Positive. 
 The genes in each of these sets were then reduced until only five members  
remained, based on availability of suitable PCR primers. All genes meeting these criteria 
were then quantified with RT-PCR on a cohort of independent RCC samples. 8 samples 
each of Clear Cell (CC) and Chromophobe (CHR) Renal Cell Carcinoma (RCC) were 
used for the study, with cDNA extractions from adjacent slices of each FFPE tissue block 
constituting duplicate samples. Two tailed t-tests were performed for each gene, 
comparing the two clinical subtypes. P-values were used to rank each biomarker in order 
of the degree of successful validation. 
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Figure 22: Venn Diagram of QC Predictions  
Red, Blue and Yellow solid shading represent the set of top genes in each of the three 
lists. Outlined areas show the predicted false positive, true positive, and false negative 




Forward and reverse primers for each of the 15 target transcripts, and the 18S 
housekeeping gene were obtained from Applied Biosystems, and quantitative RT-PCR 
was performed for 40 thermocycles on a 96-well plate. Transcripts that had not appeared 
after the 40th cycle were recorded as having Ct equal to 40. To reduce the amount of 
extrapolation and increase signal to noise ratios, samples with average 18S housekeeping 
gene expression levels higher than 17.5 Ct (indicating low overall cDNA concentration) 
were thrown out. Ct values for each of the 15 targeted genes were then normalized by 
subtracting the matched Ct values of the 18S housekeeping gene for each sample.  
Results 
 The results of the pilot study round of PCR validation are summarized in Table 4. 
Genes in the table have been ranked by p-value, such that genes near the top of the list, 
particularly the top two, can be said to be ‘validated’ as biomarkers due to their ability to 
discriminate between the two RCC subtypes. Each transcript’s place in the SVM ranking 
is shown for three cases in the rightmost columns. First the rank in unprocessed data: Pre 
Rank, Second the ranking after caCORRECT: Post Rank (All), and then the rank after 
trimming the dataset by removal of the two lowest quality chips: Post Rank (Trim). As 
can be seen in the table, the there is a trend that the best chance of validation comes from 
True Positives, followed by False Negatives, and then lastly False Positives. This trend 




Table 4: Results of PCR Validation.  
Genes predicted as true positives are shaded in yellow, False Negatives in green, and 
False Positives in Red. Ranking by p-value indicates a trend for higher validation rate for 
true positives, followed by false negatives, and finally false positives. 









202237_at NNMT Candidate RCC tumor marker J Urol 176:2248 2006 0.00000 7 6 9
201835_s_at PRKAB1 energy metabolism 0.00000 5 4 7
204396_s_at GPRK5 Signal transduction 0.00000 14 11 13
202818_s_at TCEB3 VHL partner 0.00004 7153 5049 153
208982_at PECAM1 cell adhesion 0.00011 35 160 894
201288_at ARHGDIB immune and metastasis related 0.00043 2 1 3
207042_at E2F2 major gene expression regulator 0.01725 1316 235 142
201530_x_at EIF4A1 gene expression 0.05779 4 3 4
200853_at H2AFZ chromatin 0.07660 2480 173 161
209451_at TANK immune related 0.19730 1729 106 183
36019_at STK19 MHC gene 0.21623 144 2109 1053
211020_at GCNT2 limited 0.25183 1041 1095 67
202824_s_at TCEB1 VHL partner 0.63213 7609 7316 398
203952_at ATF6 gene regulation 0.70201 56 536 1579
209778_at TRIP11 other TRIP's ass'd with hypoxia response 0.96087 76 309 1108  
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Clinical Validation Follow Up Study 
 Expanding upon the anecdotal evidence suggested by the pilot study, we 
increased the PCR panel to over 90 targets with the help of a core facility, and tried to 
expand and reproduce the pilot study which suggested that the use of caCORRECT may 
increase the reliability of biomarker selection. This time, however synthetic artifacts were 
added to the original microarray data to enhance the possible magnitude of 
caCORRECT’s impact. 
Methods 
To determine the effect that caCORRECT had on the ability to correctly identify 
biomarkers of disease from microarray data, a panel of 96 genes of interest for RCC was 
assembled for PCR study. These genes were identified from a combination of genes 
previously identified in the literature as well as a set of genes whose biomarker status was 
disagreed upon between the caCORRECT and non-caCORRECT versions of the Young 
et al. data sets (see previous section methods). All PCR analysis was performed on 
independent patient tissue samples with respect to those used for the microarray analysis. 
Gene expression was assessed by quantitative RT-PCR, using total RNA from 
fixed tissues of 17 clear cell, 13 papillary and 7 chromophobe RCC.  PCR was performed 
with a custom-designed TaqMan Low Density Array (LDA, Applied Biosystems) in a 
96-well microfluidic card format, using the ABI PRISM 7900HT Sequence Detection 
System (high-throughput real-time PCR system). Gene expression data were normalized 
relative to the geometric mean of two housekeeping genes (18S, ACTB). LDA runs were 
analyzed by using Relative Quantification (RQ) Manager (Applied Biosystems) software. 
Relative normalized gene expression was compared in renal tumor subtypes. Genes were 
declared as being “validated by PCR” if they had an average fold change between classes 
of magnitude greater than 2. 
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To measure the effect of caCORRECT in the presence of decreasing data quality, 
two new versions of  the Young et al. dataset [2] were constructed to supplement the 
original microarray data. Note that our previous study showed no significant spatial 
overlap between biomarkers and artifacts in this dataset, so any possible benefits of 
cleaning this particular data was expected to be minimal. Similar to the earlier work done 
by Jones et al., an even mixture of smaller, less-severe hot-spot and black-hole artifacts 
were applied to the chips in two sizes (see Figure 23). In order to monitor the effect of 
artifacts on differential gene finding, as well as the ability of caCORRECT to ameliorate 
those effects, Receiver Operator Characteristic (ROC) curves were used.  
Results 
Figure 23 shows examples of synthetic artifacts applied to the Young et al. dataset 
as visualized by the post-caCORRECT residual images. While the synthetic artifacts may 
appear more visually stunning than the artifacts “naturally” found in this dataset, they are 
comparable with those found on other microarrays, such as the one shown covering the 
left hand side of the chip in Figure 9. 
ROC curve analysis of microarray prediction (test prediction) versus PCR 
validation (ground truth status) is shown in Figure 24. Results show that caCORRECT 
has little effect on the predictive power of microarrays which are relatively free from 
artifacts, or contain only weak artifacts. This suggests that the use of caCORRECT is 
suitable for datasets of unknown quality without serious risk of degrading results from 
already clean arrays. Furthermore, caCORRECT is able to preserve predictive power of 
microarrays which are influenced by serious artifacts, which would otherwise suffer from 




Figure 23: Examples of Artifacts Present for Biomarker Identification Analysis.  
Images show model residuals after 4 rounds of caCORRECT normalization and artifact 
identification, but before removal. (left) The most stunning naturally occurring artifacts 
in the Young et al. dataset, (middle) a synthetic weak hot-spot artifact, and (right) a 




Figure 24: Microarray Fold Change as a Predictor of PCR Fold Change in RCC Samples, 
and the Effect of Artifacts and caCORRECT Preprocessing.  
Genes were thresholded by magnitude of observed log fold change in RMA-derived 
microarray data, and considered truly differentially expressed if they exhibited more than 
a 2x or less than a ½x fold change between classes CC and CHR in the PCR data. Only 
genes for which PCR data were available appear in this analysis. caCORRECT preserves 
data quality for normal arrays (no loss in the area under ROC curve) and improves 
quality for arrays which have serious artifacts (recovers lost area under the ROC curve). 
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Summary 
In this chapter, we have used a series of experiments, using a combination of real 
and synthetic microarray data, to show empirically how caCORRECT can impact the 
bioinformatics pipeline in various ways. The first test was designed to investigate the 
impact that artifacts may have had on previously published biomarker results. Results of 
this test showed that previously published biomarker discovery is sometimes correlated 
or anti-correlated with the presence of chip artifacts. The second test was designed to see 
if caCORRECT could improve the poor reproducibility of gene feature selection that is 
common in microarray studies. Results of this test show that caCORRECT provided a 
moderate advantage in the reproducibility of ranked biomarker lists during cross-
validation. The third test was designed to directly quantify the effect that caCORRECT 
has on the accuracy of gene expression in the presence of artifacts. Results show that 
caCORRECT reduced the RMS error of existing gene expression methodologies by 
anywhere from 20-66% depending on the nature of the artifacts and the 3
rd
 party gene 
expression algorithm being evaluated. After establishing that caCORRECT increases 
accuracy of gene expression, we then tested to determine the effect that caCORRECT has 
on the sensitivity and specificity of biomarker selection, and found that caCORRECT 
provides a moderate advantage when the raw microarray data contain serious artifacts. In 
this way, biomarkers selected using caCORRECT are more reliable, and have a better 




DEVELOPMENT OF A BIOMARKER BASED DIAGNOSIS 
 The final deliverable for this dissertation is a clinically relevant molecular 
screening for an unknown subtype of RCC. Renal Cell Carcinoma (RCC) is used as a 
case study primarily because relatively little research has been done for the molecular 
classification of RCC. Moreover, the subtyping problem for RCC is more difficult than 
simple normal versus cancerous tissue classification, and should prove to be more useful 
in a clinical setting. RCC is the most common form of kidney cancer arising from the 
renal tubule in adults [96], and more than 90% of clinically significant lesions can be 
diagnosed as one of the common subtypes of renal tumor: clear cell RCC (70-75%), 
papillary RCC (10-15%), chromophobe RCC (2-5%), or renal oncocytoma (5%). Renal 
tumor subtypes exhibit several common morphological characteristics, making diagnosis 
difficult and subjective in many cases [85]. Quantitative molecular classification is 
therefore promising as an alternative or supplement to morphological classification for 
the diagnosis of RCC. Proper classification of RCC is important, because each of its 
subtypes is associated with a distinct clinical behavior, requiring different treatment 
courses.  
RCC Biomarker Selection and PCR Validation 
 Gene biomarker selection was done as described in the earlier sections describing 
the clinical validation of caCORRECT. As part of this validation of caCORRECT, 15 
transcripts were identified (see Table 4 for a full list) for quantification by PCR. Two 
biomarkers in particular, NNMT and PRKAB1, performed exceptionally well both in the 
original microarray data (Figure 25), and during the first set of independent clinical 
samples (Figure 26). Using 18S-normalized expression for PRKAB1 and NNMT alone, 
100% classification was possible. A follow-up round of PCR on a new cohort of 9 
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chromophobe vs. 17 clear cell vs. 13 papillary was also performed, the results of which 
are also shown in Figure 26. Although a batch-effect can clearly be observed between the 
two rounds of PCR, it is still possible to design a classifier that achieves 100% separation 
between all clear cell and chromophobe samples. This separation is especially 
encouraging considering the subtle changes in protocol between the original study, 
performed by myself, Qiqin Yin-Goen, and James Torrance, and the follow up study, 
performed by a professional core facility.  
 Of the 90 markers identified by the RCC microarray experimentation, over 10 
have been verified as potentially excellent markers by follow-up PCR measurements. So 
far, only PRKAB and NNMT have been assayed for protein expression. 
 Depending on time constraints and the availability of data, this entire translational 
biomedical informatics methodology could be applied to subtyping problems other than 
Clear Cell versus Chromophobe, however currently PCR validation data is only available 
in sufficient quantities for these subtypes. Some data from Papillary RCC samples have 
also been assayed, although the number of successful PCR-validated Papillary versus 




Figure 25: Microarray Gene Expression of NNMT and PRKAB1 in RCC Tissue.  





Figure 26: Self-normalized Gene Expression of Biomarkers NNMT and PRKAB1 in 
RCC Tissue.  
Gene expression is shown in the log base 2 scale, consistent with the round of 
identification during PCR amplification. Each sample was normalized with an internal 
control by subtracting the value by the 18S value (division in the linear scale). 
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Quantitative Protein Expression Analysis 
 Because of the good results of gene based classification, NNMT and PRKAB1 
were chosen to be the first candidates for multiplexed quantum dot analysis. Multiplexed 
QD immunohistochemistry data were obtained from a Biomax BC07015 RCC tissue 
microarray stained with two antibody-conjugated Quantum Dot (QD) solutions according 
to the protocol in Xing et al.[75].  
Images were taken from each tissue sample using the Olympus IX71 microscope 
equipped with a Nuance multi spectral imager. In an attempt to minimize confounding 
variables which may undermine quantification, each image was taken with the same 
objective lens as well as with the same exposure time during a single session at the 
microscope (~2 hours total time). The fluorescence of each sample was recorded at 
wavelengths between 500 and 800nm in 10nm increments. This range was chosen 
because it corresponds to the active fluorescence emission range of the QDs. 
Quantification was done as previously described in the work by Caldwell et 
al.[16]. Briefly, a positively-constrained least-squares unmixing procedure was used for 
spectral unmixing of the two QD signatures and two known RCC autofluorescence 
signatures, followed by an average pixel intensity calculation for each unmixed QD 
component across the entire area captured by the microscope camera setup. The resulting 
data are semi-quantitative in the sense that they may justifiably be compared to each 
other quantitatively, but are not necessarily suited for direct comparison to new samples 
acquired on different microscope setups or stained with different lots of reagent. 
Initial Results 
As an initial attempt at quantitative analysis, QD-probes for the novel markers 
PRKAB1 and NNMT were multiplexed along with QD-probes for the known cancer 
marker MDM2 and a control marker β-Actin. A constrained least-squares method was 
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used to accomplish the spectral unmixing of the PRKAB1 and NNMT intensities from 
the other two QD-antibody conjugates used in the stain. From these unmixed intensities, 
pseudo colored images were produced showing both biomarkers of interest in contrasting 
color (see Figure 27). The global intensities of each QD were then calculated with a crude 
global average intensity to assess potential as features for classification (see Figure 28). 
Using a simple Bayesian classification rule under Gaussian assumption, 28/32 = 87.5% 
clear cell samples and 16/18 = 88.9% chromophobe samples are classified correctly. 
During parallel work as part of an investigation into the reproducibility and 
quantification potential of QD-IHC, it was discovered that some of these findings may 
not be directly due to protein expression. Instead, it is hypothesized that much of the 
observed NNMT signal is due to tissue autofluorescence, and imprecise unmixing. 
Furthermore, other experiments suggest that there may be significant crosstalk between 
probes which may also explain these results. Discussion of these issues is the subject of 
the next chapter. Regardless of the true nature of the signal, be it autofluorescence or 
protein biomarker, the technology does produce usable results as-is. In other words, even 
if the horizontal axis label of Figure 28 is inaccurate, the classification accuracy is 
undeniable. Even so, in an effort to do good science, this experiment was repeated with a 




Figure 27: Pseudocolored Images of Quantum Dot Staining of RCC Tissue Microarray 
Samples.  
PRKAB1 staining is shown in magenta, NNMT in green. Due to imperfect unmixing, 





Figure 28: Quantum Dot Staining of RCC Tissue Microarray Samples.  
Staining is measured in arbitrary units which are comparable across both PRKAB1 and 




In a revised protocol, Quantum Dot antibody conjugates were constructed such 
that one QD with emission peak at 605nm stained for PRKAB1, and another QD with 
emission peak at 655nm stained for NNMT. Unlike the previous experiment which 
reused secondary antibodies and stained serially, this experiment uses completely 
independent secondary antibodies, and a parallel staining protocol to minimize crosstalk. 
Furthermore, the revised protocol makes use of the two available QDs which have the 
largest signal to noise ratios with respect to tissue autofluorescence at peak emission. 
Protein analysis once again confirmed the trends observed in gene-based analysis, 
but with less reliable separation than either the PCR or the previous attempt at protein 
quantification. Figure 29 shows examples of pseudocolored photomicrographs for a CC 
and a CHR sample, as viewed with a custom-built interactive GUI.  Automated results of 
quantification, not including any region of interest selection, are shown in Figure 30. 
Investigation of photomicrographs reveals that, while overall tissue expression levels of 
NNMT were very low (< 5 Signal to Noise ratio, and <50% of autofluorescence signal), 
vascularized tissues and red blood cells were detected as expressing small amounts of 
NNMT. This suggests that the elevated levels of NNMT observed in CC samples in this 
study could also be due to the well known phenomenon of increased “chicken-wire” 
vascular patterns that are a hallmark of CC samples. Further investigation shows that 
many CHR samples which express NNMT highly were either exceptionally abundant 




Figure 29: Pseudocolored Images of Quantum Dot Staining of RCC Tissue Microarray 
Samples.  
Screenshots from our custom quantification GUI are shown for a clear cell sample (top) 
and chromophobe sample (bottom). PRKAB1 staining (QD605) is shown in red, NNMT 
(655) in green, and DAPI counterstain in blue. Regions of interest are shown outlined in 
white, with corresponding color coded spectral components shown in the bottom left 
corner of each panel. Large autofluorescence components are visible in both spectra 
plots, but the chromophobe sample has higher expression of the PRKAB1 biomarker. 




Figure 30: Quantum Dot Staining of RCC Tissue Microarray Samples.  
Staining is measured in arbitrary units, but is quantitative in nature. The trend of 
expression suggested by RNA experimentation is still evident, although it is less clear, 
possibly due to the low NNMT absolute signal levels observed in all samples. Sample 
staining is courtesy of Jian Liu. Image acquisition is courtesy of Matthew Caldwell. 
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Summary 
In Chapter 4 we have produced the first clinically relevant result attained with the 
help of caCORRECT. Using a case study of RCC clinical samples, biomarkers were first 
selected from microarray data, and then validated with quantitative RT-PCR and quantum 
dot immunohistochemistry (QD-IHC). We have shown that a RT-PCR panel of two 
markers, NNMT and PRKAB1, can be used in tandem to create an extremely high 
accuracy (100%, n = 24) RT-PCR based classification system for clear cell versus 
chromophobe RCC. We then show the results of two subsequent QD-IHC studies. The 
first study suggests accuracy as high as 88% can be achieved, but these results were not 
entirely reproducible, most likely due to a combination of high background 
autofluorescence and low signal put out by the QDs chosen for the experiment. The 
second, follow-up experiment had a higher signal to noise ratio but produced a less-clear 
classification result. A curious consequence of these two experiments suggests that 
magnitude of tissue autofluorescence may actually prove to be a viable marker for the 
differentiation of RCC tumor subtypes. Issues which lead to this low signal to noise ratio 





TOWARDS A QUANTITATIVE QUANTUM DOT METHODOLOGY 
The key challenge for quantitative multiplexed QD-IHC is the development of a 
protocol which is reproducible and reliable across technicians and laboratories. Similarly 
to the story with microarrays, without attaining such reproducibility, QD-IHC cannot 
achieve maximum impact in a clinical environment. Development of clinically viable 
method of QD-IHC represents the last major frontier to be conquered in the translational 
bioinformatics pipeline. Compared to microarray QC, QD QC is an underexplored field. 
This chapter outlines current issues which hamper reliability of QD-IHC, and discusses 
recent progress towards overcoming these challenges. Methods of spectral unmixing and 
cross-reactivity have been described in my previous publications in EMBC conference 
publications in 2008 [16] and 2009 [15], respectively.  
Spectral Unmixing Model 
 Spectral unmixing in the context of QD-IHC refers to the process of source 
separation for an observed wavelength-resolved spectrum obtained from an imaging 
device. For a typical QD-IHC experiment, sources are expected to be both the quantum 
dots used for staining as well as one or more autofluorescence signatures occurring 
naturally in tissue. Sample spectra are obtained by monitoring the fluorescence intensity 
of a stained tissue sample at multiple wavelengths in the visible and near infra-red range. 
For our microscope setup, intensity is measured at 31 equally spaced wavelengths from 
500 to 800nm.  
To spectrally unmix an entire image, one must unmix each pixel in the image. For 
simplicity of notation, but without loss of generality, we will consider only the case of a 
single pixel. The spectrum of a single pixel can be represented in a column vector, 
31ℜ∈y . Likewise, the jth isolated source spectrum of a single quantum dot or 
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autofluorescence can also be can be represented as the j
th
 column in a matrix, A, with 
dimension 31 by N (N being the total number of fluorescence sources). The observed 
spectrum, y can then be modeled by the following linear system of equations: 
 Axy =  (5.1) 
where 
Nℜ∈x  is a column vector such that the jth element of x is the magnitude of the 
contribution of the j
th
 source to the pixel’s spectrum. This unmixing model for 
fluorescence is purely additive such that the observed intensity spectrum of each pixel is 
composed of the summation of each individual QD contribution plus autofluorescence. 
Note that this model will break down when the data acquisition is saturated, so care must 
be taken not to overexpose the image. Assuming that this additive fluorescence model is 
true, and that the spectra of all sources are linearly independent, 31 wavelength-resolved 
measurements help construct an over specified system of linear equations which 
theoretically provides more than enough information to resolve even a dozen QD signals. 
In practice, however, it is rare to use more than 6 QDs at a time. Spectral unmixing is the 
process of estimating x when given only A and y. We estimate x by minimizing the mean 
squared error between y and Ax, with the constraint that the elements of x be non-
negative. This constraint ensures that all sources contribute positively to the observed 
fluorescence; in other words, QDs cannot be found to have removed light from the 
system. 
 Problems arise in the unmixing problem whenever assumptions are violated. The 
first standard assumption for solving these types of equations is that the error term, ε, is 
distributed with zero mean. The form of the equation which includes the error term is 
 εAxy +=  (5.2) 
To test this assumption, a series of pure QD in solution were monitored for 
baseline noise. For out particular imaging setup, it was found that ε is distributed with a 
median of 26 (Figure 31). Interestingly, this value did not scale with exposure time. With 
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this in mind, we reformulate the mixing equation to include baseline subtraction for each 
element of y. For our hardware setup, 
31ℜ∈b and has each element equal to 26. 
 εAxby +=− )(  (5.3) 
 It is expected that the distribution of baseline noise, and thus the values of b, will 
change from hardware to hardware. As such, each setup should be carefully tested and 
calibrated to ensure maximum accuracy. 
 
Figure 31: Box plots of Fluorescent Intensity versus Wavelength for Pure QD in Solution 
at Different Exposures. 
Images are of a drop of pure solution of QD565 in water, taken at increasing exposure 
times. Box and whiskers plots are created from the multiple pixels present in a single 




Characterization of QD and Tissue Autofluorescence Spectra 
 Integral to the solution of the unmixing equation is knowledge of the matrix, A. 
Even if one has perfect knowledge of the columns of A, corresponding to QDs based on 
manufacturer specifications or other similar analysis, the columns of A which describe 
autofluorescence components must still be derived empirically. Furthermore, we have 
found that manufacturer’s specifications for QD emission spectra cannot be trusted to be 
reproduced by our own multispectral imaging setup (Figure 32).  Using the variable 





 A single multispectral image is composed of hundreds of thousands of pixels 
which constitute a set of many different y~ . Stacking many y~ side by side to form a matrix 
Y, and stacking many x side by side to form a matrix X, allows  another re-write of the 
unmixing equation with the new feature that the rows of X may be interpreted as images, 
each of which is a single fluorescent component’s contribution to the overall image. 
 AXY =  (5.5) 
 This form of the equation is familiar to the source separation community, and 
many standard algorithms exist to learn A and X simultaneously from Y. Perhaps the 
most widely understood method is the eigen-decomposition of Y, otherwise known as 
Principal Component Analysis (PCA). In a multispectral image taken of only a single QD 
in solution, we would expect the first principal component of Y to be a good estimate of 
the column of A describing the spectrum of that QD, and this is indeed the case. If two 
QDs are mixed homogenously in solution, or if their protein targets are co-localized in a 
tissue sample, the case is less clear. In these cases, the two QD expressions are expected 
to be highly correlated with each other, and thus PCA will most likely result in the largest 
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spectral component having elements of both QDs in it. Such a result would be 
inappropriate for inclusion in the A matrix. For this reason, automated estimation of the 
columns of A should begin with either only pure, single component, images, or with 
diverse, heterogeneous images. 
 One problem with PCA is that it can produce spectral components with negative 
elements. In the context of fluorescence imaging, such a negative intensity is nonsensical 
and should be avoided. Non-Negative Matrix Factorization (NNMF) provides an 
attractive alternative to PCA in these circumstances, but comes with two caveats: NNMF 
is usually more computationally complex than PCA, and NNMF must be seeded in order 
to ensure reproducibility. A simple trick that we use to ensure reproducibility is to seed 
the NNMF with the absolute values of the results of PCA. Figure 32 shows a case study 
of the results of learning QD spectra from isolated pure solutions using PCA and NNMF 
versus the spectra supplied by the manufacturer of the QDs (Invitrogen).  
 As a further validation of use of the learned NNMF spectra, an image of a  
solution of four QDs were unmixed using both the manufacturer’s spectra, and those 
learned from NNMF as shown in Figure 32. While unmixing is the process of learning x 
from A and y, reconstruction is the reverse process, creating a model of y from x and A. 
Figure 33 shows the result of the reconstructed spectra using the manufacturer’s spectra, 
and Figure 34 shows the result when using spectra learned from NNMF.  
 Unlike QD spectra, tissue autofluorescence source spectra cannot be easily 
learned by isolating components in a solution. Autofluorescence for tissue is instead 
learned by imaging tissues that have been stained with every QD-IHC reagent except for 
the actual QDs. NNMF analysis of breast tissue, for example, yields two distinct 
components of autofluorescence. Unmixing of a multispectral image of unstained breast 
cancer tissue using these two spectra reveals two distinct tissue types which can be 
differentiated based on autofluorescence, as seen in Figure 35. 
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Figure 32: Comparison of Manufacturer Provided Spectra, PCA Spectra, and NNMF 
Spectra. 
All spectra have been normalized to have unitary Euclidean magnitude. Both of the 






Figure 33: Unmixing Result Using Manufacturer’s Spectra. 
 
 
Figure 34: Unmixing Result Using Spectra Learned from NNMF. 
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Figure 35: Pseudocolored Image Showing Two Regions of Tissue Autofluorescence in 
Breast Tissue. 
Epithelial tissue shows type 1 autofluorescence (red), glandular tissue shows type 2 
autofluorescence (cyan), and red blood cells exhibit a mixture of both. 
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Differences between QDs Affecting Interlab Comparison 
 Other factors which may affect the accuracy of absolute QD-IHC image 
quantification include the relative brightness of different quantum dots, and differences in 
the number of antibody binding events per QD. To ensure that quantification is 
independent of QD, standard curves must be created for each QD which describes the 
effect that the type of QD has on the quantification of protein. The results shown in 
Figure 33, for example show a mixture of QDs 565:605:655:706 in the ratio of 5:2:1:5. 
Even in these corrective ratios, the highest concentration QD (QD565) is still less intense 
than the most dilute QD (QD655).  This problem of weak signal for lower wavelength 
QDs is aggravated by their overlap with common tissue autofluorescent signatures (see 
Figure 36).  
 The magnitudes of these unmixed components are still in arbitrary units due to the 
uncharacterized relationship between affinity for antigen and fluorescent intensity per 
quantum dot. While these factors may be very difficult to account for, a clinically viable 
assessment of staining is still possible if reagents can be mass-produced, even if the units 
are arbitrary. To achieve such repeatability, all staining reagents must be used in 
abundance, and with sufficient incubation times to ensure that target proteins are the 
limiting factor in binding. Based on calibration data which specify the relative brightness 
of QD probes (such as shown in Figure 33), unmixed QD intensities may be scaled to 
reveal a more universally comparable measure of protein expression. Furthermore, 
comparing these intensities to standards, such as a fixed amount of pure QD in solution 
can then lead to repeatability across hardware setups.
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Figure 36: Learned Spectra of 4QDs and 2 Autofluorescent Components. 
QD spectra are colored red, cyan, magenta, and gold, and autofluorescent spectra are 
colored blue and green. All of these 31-dimensional spectra have been normalized to 




Antibody Crosstalk during Multiplexing 
 I have previously proposed a method to account for this antibody cross-reactivity 
after imaging is complete [15]. Before quantification, each image is segmented to include 
only regions of interest according to the original intended purpose of the image. For 
example, breast cancer images which are stained for progesterone receptor are segmented 
to include only glandular regions of the tissue where the protein is expected. Following 
this segmenting process, spectral unmixing is performed as usual to produce one image 
for each QD source intensity. 2D histograms are then constructed from the intensities of 
corresponding pixels from the intensity images of the first and second QD which share 
the same secondary antibody targets (Figure 37, top panel). Histograms are constructed to 
contain 256 equal-sized bins from zero to the maximum image intensity. 
 For each histogram bin of the first QD image that contains at least 20 elements, 
the bottom 20th percentile of the second QD’s intensity is estimated (Figure 37, top 
panel, green line). From the paired list (first QD intensity, corresponding second QD’s 
lower quintile), the centroids of the first and last three pairs are calculated. The line 
which connects these two centroids is called the crosstalk estimate line, and serves as a 
linear model of interaction between presence of primary antibody (as assessed by the first 
QD signal) and improper presence of secondary QD due to cross antibody reactivity 
(Figure 37, top panel, blue line). 
 The slope and intercept of the crosstalk estimate line are calculated such that the 
line may be represented by the following equation: 
 QD2_crosstalk = b + m*QD1 (5.6) 
 The observed signal for the second QD is assumed to be a combination of true 
signal and crosstalk according to the following model: 
 QD2_observed = QD2_crosstalk + QD2_true (5.7) 
 108 
 Thus, a better estimate of the true signal of the second QD can be constructed by 
subtracting the expected value of the crosstalk-component (calculated with the first QD 
signal) from the observed second QD signal. 
 QD2_true = QD2_observed – (b + m*QD1) (5.8) 
Using this correction equation, the intensity image of the second QD (Figure 37, 
bottom left panel, green color) can be modified on a pixel-by-pixel basis using the 
information from the first QD intensity image to obtain an approximation of the original 
image which has been adjusted for crosstalk (Figure 37, bottom right panel, green color). 
These images may then be quantified using standard procedures. In the example image, 




Figure 37: Observed Signal Crosstalk in Multiplexed Stained Tissues.  
Figures show a 2-D histogram of normalized and unmixed QD signals. Lines show the 
estimated cross-talk among probes used. The first QD, shown in red, was applied before 
application of the second QD, shown in green. 
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Spectral Blurring and Chromatic Aberrations 
Spectral blurring, also referred to as chromatic aberration, is a well-documented 
phenomenon whereby multicolored images appear in different focal planes according to 
the wavelength-dependent refraction (dispersion) of a lens. In its familiar form, chromatic 
aberration results in ghosted colored edges in photographs, or the appearance of rainbow 
colored stars in telescope images. For multiplexed QD multispectral images, this effect 
can be devastating because it interferes with precise spectral unmixing. Figure 39 is an 
excerpt of an unmixed and then pseudocolored photomicrograph of an RCC sample 
displaying two autofluorescence signatures in green or red. Chromatic aberration is 
visible in the image in the form of extra green halos surrounding the red objects 
(erythrocytes). 
The broad acquisition bandwidth of multispectral QD data makes it especially 
susceptible to chromatic aberration and poorly suited to traditional hardware solutions to 
chromatic aberration which couple two dispersive media together. Software solutions for 
correcting aberration in RGB images, such as that proposed by Kaufmann et al. [97], 
exist and are included in most modern high-end consumer digital cameras. Such methods 
work by post-imaging modification (registration) of the red and blue images to match the 
green image. Extending this methodology to a multispectral image is also possible, 




Figure 38: Pseudocolored Image Excerpt of RCC Tissue Autofluorescence which 
Demonstrates Chromatic Aberration. 
Red blood cell autofluorescent signature is pseudocolored red, while renal tissue 
autofluorescence is pseudocolored green. 
 
 
Figure 39: Pseudocolored Image of RCC Tissue Autofluorescence which Demonstrates 
Chromatic Aberration. 
Red blood cell autofluorescent signature is pseudocolored red, while renal tissue 
autofluorescence is pseudocolored green. 
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As a precursor to correcting for aberration, a function describing the aberration 
must first be estimated. We begin by considering the image shown in Figure 39. A local 
correlation search was performed by selecting a window in the blue end of the spectrum 
and translating it locally many times. Each time we noted the correlation of the 
windowed blue spectrum image with the corresponding red image, which is held still. For 
each window, the direction and distance of translation which corresponds to the 
maximum correlation of overlapped windows was recorded. Because the image in 
question is composed largely of a broad-spectrum fluorescence, it is reasonable to expect 
the blue spectrum image to correlate well with the red spectrum image. This would not be 
the case for a multiplexed quantum dot image, for example. A color-coded map of the 
direction and magnitude of the estimated “maximum correlation” translations are shown 
in Figure 40. 
As shown in Figure 40, the apparent chromatic blur was in a radial direction from 
the center of the image, with a magnitude that increases with distance from the center. 
This analysis should be repeated for each of the 31 spectral images, with one acting as a 
point of reference. After acquiring this empirical measure of the microscope’s chromatic 
aberration for each wavelength, a geometric model of this aberration could be 
constructed. An example of such a function would be a linear increase with distance from 
the center, but more complicated models are possible, depending on the microscope 
setup, and focal plane. Once a suitable model is created for each wavelength image, they 






Figure 40: Map of Direction and Magnitude of Spectral Blurring. 
Direction is given in radians, and distance in pixels.  
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Summary 
In this chapter, we have discussed issues which currently prevent a reproducible 
and reliable quantitative multiplexed QD-IHC protocol from becoming a clinical reality. 
Despite current shortcomings, semi-quantitative results, such as those discussed in 
chapter 4, are currently achievable with proper controls and calibrations. Chief among 
outstanding issues is the physical aspect of the assay, which is having the intended 
reporter molecules attach to their intended targets in a linear and dose-dependent manner. 
In this respect, the mathematical and software solutions for proper unmixing and 
quantification appear to be more mature than the physical and biochemical aspects of the 
assay. For example, we have shown that characterization of the source spectra for these 
images is an achievable, even if sometimes overlooked, portion of protocol. Furthermore, 
we suggest that a simple model can be combined with current methods of spectral 




To achieve the three specific aims of this research, three concrete deliverables 
were produced. These deliverables are: caCORRECT, validated biomarkers for RCC, and 
results of an investigation into the challenges QD-IHC. This chapter concludes the 
dissertation by offering a discussion of the current status of these deliverables, followed 
by a future outlook on these and related topics 
Contributions to the Field 
caCORRECT 
In chapters 2 and 3, we have proposed and validated a microarray quality control 
system, caCORRECT. Descriptions of methods are found in this document, as well as in 
previous publication [11]. Much of the newer validation work is expected to be published 
concurrently in an appropriate peer-reviewed scientific journal. Source code for the 
version of caCORRECT described in this document is written entirely in MATLAB by 
me, with some recent help from Mitch Parry. Documentation of this code is maintained 
on our internal intralab wiki page, with the help of Mitch Parry. In addition to the 
MATLAB development version of caCORRECT, two other instances also exist. First, the 
Enterprise version of caCORRECT is implemented in PHP, JavaScript, C and C++ codes 
written mostly by myself and Todd Stokes., with help from JT Torrance and John Phan. 
The enterprise version exists as a web service, which has been freely available to the 
public at caCORRECT.bme.gatech.edu since the spring of 2007. The website is currently 
maintained by Sovandy Hang. The final implementation of caCORRECT is a grid service 
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as part of the National Cancer Institute’s Cancer Bioinformatics Grid (caBIG). 
Conversion of caCORRECT into the caBIG grid service format and creation of 
associated silver-level compatibility review documents were done by Martin Ahrens and 
Todd Stokes. 
Biomarkers 
In chapter 4, Development of a Biomarker Based Diagnosis, we share the results 
of biomarker discovery, aided by caCORRECT, using a case study of Renal Cell 
Carcinoma (RCC) clinical samples. In this document, we focus on the thorough 
validation of two such markers, NNMT and PRKAB1, which allow 100% classification 
accuracy in 24 independent validation samples. In addition to these two well-studied 
markers, more than 10 other potential clinical markers have also been discovered during 
this process. These other markers represent the results of large scale collaborative study 
which are not appropriate for direct inclusion in this dissertation. Instead, these markers 
may be found in two other publications that I have contributed to: Phan et al, 2009 [98] or 
Osunkoya et al., 2009 [13]. 
Quantum Dot Methodology 
As discussed in Chapter 5, QD-IHC has major potential as a clinical tool for 
sensitive and specific molecular diagnosis and prognosis of disease. Motivated by this 
potential, this dissertation has outlined key areas of improvement which must be made 
before translating QD-IHC to the clinic. Such a critical discussion is rare in the literature, 
which tends to focus on success rather than perceived failures in protocol. Despite these 
issues, data from existing duplex QD-IHC protocols have been used as a successful 
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demonstration of semi-quantitative comparison which can help separate two subtypes of 
RCC with moderate accuracy. 
Future Outlook 
caCORRECT 
The current status of caCORRECT is a complete and functional system which 
includes many novel contributions. Further improvements of the various modules of 
caCORRECT are expected to be incremental in nature and have diminishing returns on 
investment. Such incremental impotents could be made by: (1) increasing the complexity 
of artifact masking procedures, using an array of kernels designed for common artifacts, 
(2) incorporating the complexity of existing 3
rd
 party gene expression models into 
caCORRECT’s modeling procedure, or (3) further investigate convergence of multiple 
rounds of artifact detection, and testing the possibility of fuzzy artifact classification. 
Originally, these ideas were shelved to accommodate the user’s need for speed, and these 
issues have yet to subside as the size of microarray datasets seems to be scaling along 
with computer hardware capabilities.  
Aside from these incremental improvements, the broader impact of caCORRECT 
could be improved by porting the same methodologies to other array platforms or 
technologies. We have already accomplished a proof of concept for the Illumina 
BeadChip platform [10], but many other applications exist, including the emerging field 
of QC for next-generation sequencing technologies. The pending incorporation of 
caCORRECT as a caBIG grid service is expected to help increase broader impact as well. 
To increase the impact and use of caCORRECT in the community, we must show 
that caCORRECT has a retroactive impact on the quality of previous microarray 
experiments. To show this, we will now revisit the results of previously high-impact 
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published papers to see if good biomarkers can be found after caCORRECT treatment of 
raw data.  
On another frontier, Todd Stokes’ system, ArrayWiki [57], is now the premiere 
platform for showcasing caCORRECT, and it is also responsible for the most uses of 
caCORRECT, beyond even my own use. ArrayWiki is an open wiki repository for 
microarray data which includes mandatory preprocessing with caCORRECT for all new 
data imports. Importantly, ArrayWiki also displays heat maps from caCORRECT for 
every microarray. As ArrayWiki grows to incorporate a higher percentage of the world’s 
microarray data, so grows the impact of caCORRECT. 
Biomarkers 
Here, we have highlighted the discovery of a two-gene panel of biomarkers for 
subtyping between two classes of RCC. Clearly, much work is left to be done before we 
are able to claim a truly clinically relevant test for RCC. Specifically, we must develop a 
panel of biomarkers that is suitable for the differentiation of all five of the common 
subtypes of RCC, and not just CC and CHR. From the available PCR data which was 
collected as a byproduct of proving caCORRECT’s effect on reliability of biomarker 
selection, we are able to create such a panel, but it is yet to be verified as reliable based 
on independent clinical samples. Future work will involve creating optimal sets of 
biomarkers for simultaneous differentiation of multiple clinical subtypes of RCC.  
Although such a PCR-based test would be valuable indeed, the search for more 
sensitive techniques of biomarker-based analysis is also ongoing. This includes not only 
the QD-IHC discussed here, but also bimolecularly specific methods of circulating tumor 
cell [74, 99-104] or blood-bourn biomarker detection [105, 106]. Notable failures of 
reproducibility in these fields highlight the need for QC in all aspects of biomarker 
identification [107-110]. 
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Quantum Dots as a Clinical Technology 
The reliable quantification of QD-IHC is of critical importance to its clinical 
translation. To achieve this, we must first start with a basic assessment of QD 
quantification in a cell and antibody free environment. Some work has already been done 
to assess the dynamic range and detection sensitivity limit of QDs in large beads [111], 
but not necessarily in the single antibody-conjugated nanoparticle form that is the most 
likely form for a clinical application.  
Our own observations, as well as those of others [112], have confirmed that QDs 
can undergo time-dependent photo brightening or photo darkening. Such time-dependent 
effects represent a significant hurdle to quantification, and thus work to assess and 
stabilize QD signal over time are needed. Similarly, there is also a need to increase the 
relative brightness of QD signal with respect to tissue autofluorescence [74, 76]. Some 
progress has been made to increase signal to background using the unique properties of 
QD i.e. long emission half-life [79], or relative photostabillity [75, 80]. Unfortunately, 
most of the existing solutions for increasing the QD signal to autofluorescence signal 
ratio involve techniques which also affect the brightness of QDs, and are thus difficult to 
apply directly to a quantitative protocol. 
Aside from these issues related to the optical properties of QDs, quantitative IHC 
even without QDs has its own problems. Although some systems, such as AQUA [113] 
have been proposed to quantify staining, reproducibility outside of highly-controlled 
tissue microarrays has yet to be demonstrated. Using improper antibody concentrations 
which cause nonlinear response to antigen has been linked to failure in a past study, 
notably by the developers of AQUA [114]. To combat these common issues of IHC and 
QD-IHC, we must conduct basic sample-free antigen capture experiments to verify and 
quantify linear binging of probes to targets. 
The capacity of QD-IHC to be highly multiplexed invites further room for quality 
control. In addition to limiting antibody cross-reactivity, more basic issues of QD-to-
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target binding persistence must be investigated with respect to the increased number of 
washing and incubation steps required in multiplexed assays. To do this, we have begun 
to investigate sample-free serial binding and disassociation kinetics. 
Quantum dots are not the only emerging technology which shows promise for 
multiplexed analyses of tissue biopsies; Surface Enhanced Raman Spectroscopy (SERS) 
nanotags have also been proposed for in-situ protein analysis of tissue specimens [115-
117]. Due to their complex spectra, SERS tags have a higher potential for molecular 
specificity during imaging, but also require more sensitive instrumentation, and more 
computation to achieve these advantages. Just like QD tags, SERS tags face the same 
problems of antibody cross talk, yet they have the potential to be more easily separated 
from background tissue autofluorescence signals. SERS work should be able to borrow 
many spectral unmixing solutions from another spectral tissue imaging technology, 
Imaging Mass Spectrometry (IMS) [3, 118-122]. IMS has the advantage of being 
antibody-free, but is severely limited by spatial resolution as well as high cost—making it 
currently unsuitable for clinical application. 
Closing Remarks 
Both the development and implementation of a clinical biomarker test require 
quality control to ensure efficiency and reliability. Examples of this include insurance of 
the best possible microarray data being fed into the pipeline, as well as reproducible 
quantification of IHC results at the point of clinical contact. This dissertation represents a 
significant step forward in achieving these goals of quality, reliability, and reproducibility 
of each piece of the translational bioinformatics pipeline. Future work is expected to 




SOLUTION OF GENE EXPRESSION MODEL 
The model which describes the relationship between observed probe intensities 
(raw chip data) and gene expression (data for modeling) is described by the following 
equation, previously given in chapter 2. 
 pbjpjpb
ax ,,,, θ=  (A.1) 





 probe set on the j
th 
chip, jp,θ  is the gene expression term corresponding to target 
RNA concentration, and pba ,  is the lumped probe affinity term. This appendix discusses 
the ways in which this equation is practically solved. 
Discussion of Error Term 
 This gene expression model can be interpreted with different error models. In 
each case, jpb ,,ε  and or jpb ,,ε ′ will represent the error terms which contribute to the 
observed intensity jpbx ,, . One error model option is additive in the domain of probe 
intensity. In this case, jpb ,,ε  represents noise that is independent of the intensity signal. 
 jpbpbjpjpb
ax ,,,,,, εθ +=  (A.2) 
Another interpretation is that error is multiplicative in the domain of probe 
intensity, which is equivalent to additive in the log domain of probe intensity. In this 
case, jpb ,,ε ′  represents noise that is proportionate to the intensity signal. 
 jpbpbjpjpb
ax ,,,,,, εθ ′=  (A.3) 
-or- 
 
)log()log()log()log( ,,,,,, jpbpbjpjpb ax εθ ′++=  (A.4) 
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In reality, the noise may be best modeled as a combination of these two types of 
additive and multiplicative noise. 
 jpbjpbpbjpjpb
ax ,,,,,,,, εεθ +′=  (A.5) 
Figure 41 shows an example of real data from the Young dataset for a single 
probe set selected for its relatively large dynamic range. Figure 42, Figure 43, and Figure 
44 show simulated probe data in the same range as Figure 41 with additive, multiplicative 
and combination models of noise, respectively. caCORRECT uses an additive model by 
default, but options exist to use a multiplicative model as well. The additive noise model 
is chosen over the multiplicative noise model for superior stability in the face of low-
expressing genes. 
According to the model, data from each probe set are independent of one another, 
and contain no common terms. Thus, reconstructing the probe intensity model equation 
for each observed probe intensity on each chip in a dataset produces a series of P 
independent sets of equations, where P is the total number of probe sets represented on 




Figure 41: Plot of Gene Expression Versus Probe Intensity for Real Data. 
A mixture of intensity dependent and independent noise is observable. 
 
Figure 42: Plot of Gene Expression Versus Probe Intensity for Simulated Data with 
Additive Noise. 
Residuals converge for high intensities when viewed on the logarithmic axes. 
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Figure 43: Plot of Gene Expression Versus Probe Intensity for Simulated Data with 
Multiplicative Noise. 
Residuals converge for low intensities when viewed on the linear axes. 
 
 
Figure 44: Plot of Gene Expression Versus Probe Intensity for Simulated Data with a Mix 
of Additive and Multiplicative Noise. 
Residuals do not appear to converge for either of the scaled axes. 
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Solution of Additive Gene Expression Model 
 The set of equations for the p
th
 probe set using an additive model of error can be 








































































 For ease of notation, we will refer to this equation in a condensed form as follows. 
 pppp εaθX +=  (A.8) 
We define the solution to this matrix equation as that which minimizes the 














,,εε  (A.9) 
To be able to come up with a unique solution, we introduce the constraint that the 
geometric mean of the lumped probe affinity terms pba ,  equals one. The number one is 
arbitrary here, but it allows the convenient interpretation that the values of gene 



















The solution which satisfies the above conditions can be derived from the singular 
value decomposition (SVD) of pX . Here, the SVD of pX  is given in the form of 
T
USVX =p , such that
NNxℜ∈U , p
xBN
ℜ∈S , and pp
xBB
ℜ∈V . If the largest singular value 
in S, s1, is arranged as the first diagonal element of S, then pθ is s1 times the first column 
of U and pa is the first column of V. Once derived from the SVD, pa  and pθ  may then 
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be scaled by respective multiplication and division by a single factor in order to satisfy 
the geometric mean constraint as stated earlier. 
If we assume that pX is rank 1, (that it can be perfectly approximated by the 
multiplication of a single column vector pθ  and single row vector pa ), then we can use a 
shortcut to estimate pθ and pa  directly from pX  without using an SVD. In such a 
situation the summation of the b
th
 column of pX would give a clue to the b
th 
element of 
pa  as follows. 

















,, θθ  (A.11) 
This b
th
 column summation of pX  is defined as pbφ , , which can then be 
combined into a row vector, pφ . 








,,,1,,1 θLLφ  (A.12) 
In this form, we can see that pφ  is simply a scaled version of pa . Because of the 
geometric mean constraint on pa , pa  can be easily derived from pφ by normalizing pφ  















a  (A.13) 
Similarly, summation of the j
th
 row of pX would give a clue to jp,θ . 

















,, θθ  (A.14) 























,θ  (A.15) 
Incorporation of artifacts into this model is done in the following 2-step iterative 
procedure similar to the Expectation-Maximization algorithm. This procedure, given 
below, is repeated until pθ and pa converge 
1) Estimate pθ and pa given pX , either using the SVD or the mean approximation as 
described previously. 
2) Replace known artifact values in px with information from the corresponding 
elements of ppaθ .  
Solution of Multiplicative Gene Expression Model 
 The set of equations for the p
th
 probe set using a multiplicative model of error can 

















































































































































































































































































































































































































































=′ T  (A.17) 
 Like in the additive noise model, we must also introduce a constraint on pa′  to 
achieve a unique solution. In the case of multiplicative noise, however, we represent this 












0  (A.18) 
 In this form, the constraint can easily be incorporated into the existing matrix 
equation structure by appending a zero to the bottom of px′  and a row consisting of N 
zeros, followed by Bp ones to the bottom of Mp. In this augmented form, it is 













given data from px′ , and the fixed coefficient matrix, 
Mp in a way that minimizes an error which is the Frobenius norm of pε′ . The Frobenius 












,, )log(εε  (A.19) 
The solution to this error minimization is given by the following equation, which 
uses the pseudo-inverse of Mp. The superscript 
T
 represents the matrix transpose. 
















xMMM  (A.20) 
Note that because the constraint on pa′  is completely achievable, we do not need 
to worry about it being codified here as a “soft” constraint as part of a least squares 
optimization. 
Incorporation of known artifacts into this model is also rather straightforward. 
One way to ignore artifacts is to simply excise the rows of px′  and Mp which contain 
 129 
artifactual data. In rare cases, however, noisy data can lead to excessive excision that can 
in turn result in pp MM
T
being singular, and so this method is not preferred. An 
alternative method is to multiply the rows of px′  and Mp which contain artifactual data by 
a small number, such as the 0.1 used by caCORRECT. This has the effect of down-
weighting any residuals derived from artifact data during the optimization. Because the 
data are not completely excised, pp MM
T
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